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ABSTRACT 
Study of the mechanisms underlying the cytotoxic effects of bovine 
lactoferrin on breast cancer cells 
Lactoferrin (LF) is an iron-binding protein predominantly found in mammalian secretions. 
This protein and its variants have been proposed for cancer therapy for many years owing 
to their tumor-targeting properties. Previous studies showed that LF and its derived 
peptides inhibit the proliferation of cancer cells. However, the detailed mechanisms by 
which LF exerts its effect are still fairly unknown. Moreover, there are few reports 
concerning LF effect on breast cancer cells, which is one of the most common malignant 
tumors in the World.  
In this sense, the present thesis aimed to investigate the cytotoxicity of bovine lactoferrin 
(bLF) and its variants against several breast cancer cells, namely T-47D, MDA-MB-231, 
Hs578T and MCF-7 cell lines. The results showed that bLF at concentrations of 1.875 μM, 
3.75 μM, 7.5 μM, 15 μM and 30 μM could efficiently inhibit the growth of cancer cells but 
showed a very low effect on normal breast cells (MCF-10-2A). Moreover, its variants 
(apo-bLF, holo-bLF and LfcinB17-41) were also able to inhibit cancer cells’ growth, except 
for LfcinB26-36. Additionally, bLF, apo-bLF and holo-bLF did not promote the proliferation 
of breast cancer cells at low concentrations (0.25 μM, 0.5 μM and 1 μM) as reported for 
other cancer cell lines. Simultaneously, the degradation assay excluded the possibility that 
bLF anticancer effects could be due to its degraded peptides under cell culture conditions. 
On the other hand, it was found that most of the bLF was blocked outside the cells, despite 
that a few amount was able to be internalized to the cytoplasm. Its peptide LfcinB17-41 also 
succeeded in penetrating the cell membrane but could not enter the nucleus.  
Subsequently, we found that the inhibitory effects of bLF on the breast cancer cells resulted 
from the cell cycle arrest without effects in cell death by apoptosis. Depending on the cell 
lines, this prevention of cell cycle progression induced by bLF occurred at different phases. 
Nevertheless, the MAPK/ERK and PI3K/AKT signaling pathways were not implicated in 
the cell cycle arrest observed. bLF anticancer effect was associated, however, with an 
increase of AMPKα phosphorylation and a decrease in the levels of mTOR and its 
phosphorylation. To our knowledge this is the first time this pathway has been implicated 
in the mechanisms underlying bLF cytotoxicity against cancer. These findings suggest that 
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bLF could be a new mTOR-targeting drug in cancer therapy. However, it is important to 
notice that no apoptotic cells could be found in bLF-treated cancer cells. 
The use of higher bLF concentrations (12.5 μM, 50 μM, 125 μM and 175 μM) was 
expected to exhibit different effects on the breast cancer cells as compared with the low 
concentrations range. In fact, in the high range of concentrations bLF selectively induced 
cell death by apoptosis in MCF-7 cells. The mechanisms of bLF-induced apoptosis 
included the intrinsic pathway since it was observed the mitochondrial membrane 
depolarization and a decrease in Bcl-2 levels. In addition, bLF also induced significantly 
the cell cycle arrest of these cells at the G1 phase, while the same concentration of another 
protein source (bovine serum albumin - BSA) did not affected significantly the cells. This 
suggests that bLF cytotoxicity is not due to the addition of great amounts of exogenous 
proteins in the cell microenvironment. The western bolt analysis confirmed that bLF 
blocked the cell cycle progression by adjusting cell cycle related regulators, such as 
CDC25c. Additionally, bLF showed a clear inhibitory effect on the MCF-7 cells ability to 
form colonies, which is one of the favorite features of anticancer drugs for preventing 
metastasis. We also found that the promoting effect on the migration of MCF-7 cells may 
be due to the fact that bLF changes cell microenvironment positively for cell migration 
similarly to BSA.  
The results gathered in this thesis demonstrated the potential of bLF as an anticancer agent 
and provided some new insights on its mechanisms of action. However, further work is 
still required before bLF can be considered for clinical applications. Being a food-derived 
protein, bLF is commonly consumed in the daily life, as well as in supplements for health 
care. Nevertheless, the relation between its consumption and cancer prevention remains to 
be elucidated.  
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RESUMO 
Estudo dos mecanismos subjacentes aos efeitos citotóxicos da lactoferrina 
de origem bovina em células de cancro da mama 
A Lactoferrina (LF) é uma proteína com alta afinidade para ligação ao ferro, 
predominantemente encontrada nas secreções dos mamíferos. Esta proteína e as suas 
variantes têm vindo a ser propostas como agentes interessantes para a terapia do cancro. 
Estudos anteriores mostraram que a LF e os seus péptidos inibem a proliferação de células 
cancerígenas. No entanto, os mecanismos detalhados pelos quais a LF exerce o seu efeito 
são pouco conhecidos. Além disso, há poucos estudos sobre os efeitos da LF em células de 
cancro da mama, que constitui um dos tumores malignos mais comuns a nível mundial. 
Neste sentido, na presente tese pretendeu-se estudar a citotoxicidade da lactoferrina de 
origem bovina (bLF) e das suas variantes contra várias linhas celulares de cancro da mama, 
nomeadamente T-47D, MDA-MB-231, Hs578T e MCF-7. Os resultados mostraram que a 
bLF em concentrações de 1,875 µM , 3,75 µM, 7,5 µM, 15 µM e 30 µM inibe 
eficientemente o crescimento de células cancerígenas, mas apresenta um efeito muito 
pouco pronunciado nas células normais da mama (MCF-10-2A). Além disso, as suas 
variantes (apo-bLF, holo-bLF e LfcinB17-41) também foram capazes de inibir o 
crescimento das células cancerígenas, exceto o péptido LfcinB26-36. Adicionalmente, a 
bLF, apo-bLG e holo-bLF não promoveram a proliferação das células cancerígenas a 
baixas concentrações (0,25 µM , 0,5 µM e 1 µM) tal como foi relatado para outras linhas 
celulares. Adicionalmente, excluiu-se a possibilidade de que os efeitos anti-cancerígenos 
da bLF possam ser devidos aos seus péptidos resultantes da degradação da proteína sob as 
condições de cultura das células. Por outro lado, verificou-se que a maior parte da bLF é 
bloqueada no exterior das células, apesar de uma pequena quantidade internalizar a célula 
para o espaço citoplasmático. O péptido LfcinB17-41 também conseguiu penetrar a 
membrana celular mas não o núcleo. 
Subsequentemente, verificou-se que os efeitos inibidores da bLF sobre as células 
cancerígenas da mama resultaram da paragem do ciclo celular, sem se ter observado um 
efeito na morte celular por apoptose. Dependendo das linhas celulares, esta paragem do 
ciclo celular induzida pela bLF ocorreu em diferentes fases. No entanto, não foi possível 
associar as vias de sinalização MAPK/ERK e PI3K/AKT ao efeito observado no ciclo 
celular. Por outro lado, o efeito anti-cancerígeno da bLF foi associado a um aumento da 
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fosforilação da AMPKα e a uma diminuição dos níveis de mTOR e da sua fosforilação. 
Esta é a primeira vez que esta via foi associada aos mecanismos subjacentes à 
citotoxicidade da bLF contra células de cancro. Estes resultados sugerem que a bLF poderá 
ser uma nova droga, cujo alvo é a proteína mTOR, a explorar na terapia do cancro. No 
entanto, é importante notar que não se observaram células apoptóticas em nenhuma das 
linhas celulares tratadas com bLF. 
Aquando da utilização de concentrações de bLF mais elevadas (12,5 µM, 50 µM, 125 µM 
e 175 µM) esperava-se que as mesmas exibissem diferentes efeitos sobre as células 
cancerígenas comparativamente com a gama de baixas concentrações. Na verdade, para 
concentrações de bLF elevadas observou-se uma indução selectiva de morte celular por 
apoptose nas células MCF-7. Os mecanismos de apoptose induzida pela bLF incluiram a 
via intrínseca no sentido em que se detectou a despolarização da membrana mitocondrial e 
a diminuição dos níveis de Bcl-2. Adicionalmente, a bLF também induziu 
significativamente a paragem do ciclo celular destas células na fase G1, enquanto que uma 
concentração similar de outra proteína (albumina do soro bovino - BSA) não afectou 
significativamente as células. Isto sugere que a citotoxicidade da bLF não é devida ao facto 
de se adicionarem grandes quantidades de proteína exógena ao microambiente celular. Pela 
técnica de Western blot confirmou-se que a bLF bloqueia a progressão do ciclo celular, tal 
como mostrou a diminuição dos níveis da proteína CDC25c. Por outro lado, a bLF mostrou 
um efeito inibidor evidente sobre a células MCF-7 no que se refere à sua capacidade para 
formar colónias, o que constitui uma das características desejadas em fármacos 
anti-cancerígenos para prevenir as metástases. O efeito promotor da bLF sobre a migração 
de células MCF-7 pode ser devido ao facto desta proteína modificar o microambiente 
celular de uma forma positiva para a migração celular, tal como se observou com a 
utilização de BSA. 
Os resultados obtidos nesta tese demonstraram o potencial da bLF como agente 
anti-cancerígeno e permitiram esclarecer possíveis mecanismos envolvidos na sua 
atividade. Todavia, é ainda necessário conduzir mais trabalho de investigação antes que 
bLF possa ser considerada para aplicações clínicas. Sendo uma proteína derivada de 
alimentos, a bLF é vulgarmente consumida na alimentação humana, bem como em 
suplementos para a saúde. No entanto, a relação entre o seu consumo e a prevenção do 
cancro continua por elucidar. 
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Coomassie blue staining. (B) bLF degradation assay by Tricine-SDS-PAGE. Cells were 
treated with bLF for 24 h, 48 h and 72 h. Medium samples containing bLF were loaded in 
Tricine-SDS-PAGE gels and proteins were visualized by Coomassie blue (a, b) and silver 
staining (c, d), respectively. Shown gels are representative of threeindependent 
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condensation assay after 72 h incubation with 30 μM bLF. (B) Apoptotic cells in T-47D 
and MDA-MB-231 cell lines were evaluated by the annexin V/ PI assay after 24 h 
incubation with 30 μM bLF. Results correspond to a representative experiment from three 
independent experiments with similar results. 
Figure 3.2 – Expression of JNK and p38 pathways in breast cancer cells exposed to bLF. 
T-47D, MDA-MB-231 and MCF-7 cells were incubated with different bLF concentrations 
for 48 h. The protein level of JNK and p38 in these cells were evaluated by western blot. 
The blots are representative of three independent experiments with similar results. β-actin 
was used as loading control. 
Figure 3.3 – Cell cycle progression in breast cancer cells exposed to different bLF 
concentrations for 48 h. T-47D, MDA-MB-231, Hs578T and MCF-7 cells were incubated 
with different concentrations of bLF for 48 h, and the cell cycle of cells were analyzed by 
flow cytometry. These are representative results from three independent experiments with 
similar results.  
Figure 3.4 – Effect of bLF in the ability to induce DNA double-strand breaks, as measured 
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by the phospho-histone H2A.X levels. This was evaluated in T-47D cells by western blot 
after incubation with bLF at 15 μM and 30 μM for different time points. Etoposide at 50 
μM was used as positive control. The image is the representative bots of three independent 
experiments.  
Figure 3.5 – Expression of ERK and AKT pathways in breast cancer cells exposed to 
different bLF concentrations for 16 h, as assessed by western blotting. This experiment was 
repeated three times with similar results. β-actin was used as control. 
Figure 3.6 - Short-term effects of bLF on the phosphorylation of ERK and AKT. Cells 
were incubated with 15 μM bLF for 30 min, 1 h, 2 h, 3 h and 6 h (there were no medium 
change when bLF was added). The protein level of p-ERK and p-AKT in T-47D (A) and 
MDA-MB-231 (B), respectively, was analyzed by western blot. β-actin was used as 
loading control. This image is representative of three independent experiments with similar 
results. 
Figure 3.7 – Evaluation of bLF effect in the expression of phospho-mTOR and mTOR 
levels in several breast cancer cell lines. Cells were incubated with the same concentration 
of bLF for 2 h and 20 h (A) or treated by different concentrations of bLF for 16 h (B). The 
relative protein levels in the respective cells were measured by western blot. The blots are 
representative of three independent experiments with similar results. β-actin was used as 
loading control. 
Figure 3.8 – Evaluation of the bLF effect on the expression of AMPKα and CDC25c in 
breast cancer cells. Cells were incubated with different concentrations of bLF for 48 h and 
the protein level of phospho (p) - AMPKα, AMPKα and CDC25c were evaluated by 
western blot. Shown bots are representative of three independent experiments with similar 
results. β-actin was used as loading control. 
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Figure 4.1 - Effect of bLF on breast cancer cells’ growth. MCF-7, T-47D, MDA-MB-231 
and Hs578T cells were incubated with bLF at several concentrations for 48 h and cell 
growth evaluated by cell counting of viable cells (not stained with trypan blue). Values are 
mean  SD of three independent experiments. * P < 0.05 and ** P < 0.01 when compared 
with the control. 
Figure 4.2 - Effect of bLF in the induction of cell death by apoptosis in MCF-7 cells. Cells 
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were treated with different concentrations of bLF for 40 h or 72 h and apoptosis estimated 
by the Annexin V/PI and the nuclear condensation assays, respectively. (A) Representative 
images of the nuclear condensation assay where apoptotic cells are shown with arrows: 
white arrows correspond to examples of early apoptotic cells (condensed DNA); red 
arrows correspond to examples of late apoptotic cells (condensed and fragmented DNA). 
Images are provided with a magnification of 400×. (B) Apoptosis rate induced by bLF as 
mean  SD of three independent experiments, as estimated by the nuclear condensation 
assay. * P < 0.05 and ** P < 0.01 when compared with the control. (C) Apoptosis assay by 
Annexin V/PI representative of two independent assays.  
Figure 4.3 - Effect of bLF in the cell cycle progression of MCF-7 cells. (A) Cells were 
incubated with bLF at several concentrations for 24 h and cell cycle was analyzed by flow 
cytometry. Results correspond to a representative experiment from three independent 
experiments. (B) Comparison between the effect of bLF and BSA at the same 
concentration on the cell cycle progression of MCF-7 cells after 24 h of treatment. The top 
image is representative of cell morphology for each condition (magnification of the images: 
40×). 
Figure 4.4 - Effect of bLF on the mitochondrial membrane potential. (A) MCF-7 cells 
were incubated with bLF at several concentrations for 2 h, 24 h and 48 h and mitochondrial 
membrane potential was analyzed by flow cytometer after labeling cells with JC-1 
fluorescent probe. The red/green ratio was calculated from the respective median 
fluorescent value, where a decrease of this value in comparison to the control is indicative 
of mitochondrial membrane depolarization. Values correspond to the mean  SD of three 
independent experiments. * P < 0.05, ** P < 0.01 and *** P < 0.01 when compared with 
the control. (B) The top image is representative of cells labeled with JC-1 probe, where red 
cells contain polarized mitochondria and green cells contain depolarized mitochondria 
(magnification of the images: 400×). The bottom image corresponds to JC-1-labeled 
MCF-7 cells after 48 h of treatment with positive control (50 μM CCCP) or 175 μM bLF 
analyzed by flow cytometry. The graphs exhibit the percentages of cells with depolarized 
mitochondria (green positive/red negative).  
Figure 4.5 - Levels of Bcl-2, p53 and CDC25c in MCF-7 cells after treatment with bLF at 
several concentrations for 48 h, as measured by western blotting. The blots are 
representative of three independent experiments with similar results. -Actin was used as 
xx 
 
loading control. 
Figure 4.6 - Effect of bLF on the MCF-7 cells ability for anchorage-dependent colony 
formation. (A) Cells were seeded at low density and incubated with several concentrations 
of bLF and DMEM (FBS-free medium) for 24 h. Then, cells were left for 1 week to grow 
in complete medium to form colonies from single cells. Colonies were fixed, stained and 
images were captured. (B) Quantification of colony formation as mean  SD of three 
independent experiments. ** P < 0.01 and *** P < 0.001, when compared with the control 
(0 μM bLF).  
Figure 4.7 – Effect of bLF on the migration of MCF-7 cells. Cells were incubated with the 
same concentration of bLF and BSA for 6 h, 12 h and 24 h. (A) Representative images of 
cell migration into the wounded area after 24 h of incubation (Magnification: 40×) (B) 
Relative wound closure as measured by Image J software. Results correspond to the mean 
 SD of three independent experiments. * P < 0.01 and ** P < 0.01 when compared with 
the control or among each other.  
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LIST OF ABBREVIATIONS  
AKT Protein Kinase B 
AMPK AMP-activated serine/threonine protein kinase 
Apo-LF    Iron-free lactoferrin 
BRCA2 Breast cancer susceptibility gene 
BSA Bovine serum albumin 
CAPs Cationic antimicrobial peptide 
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COUP-TF Chicken ovalbumin upstream promoter transcription factor 
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Preface 
   
The last few decades have been fruitful in great discoveries and advances in medicine. 
However, cancer is still an unsolved issue in modern medicine. According to the American 
Association for Cancer Research Progress Report, global cancer incidence is predicted to 
increase from 12.8 million new cases in 2008 to 22.2 million in 2030. Although more 
people survive to cancer today than in the past, this trend is confined to some types of 
cancer. The survival rates of some cancers, such as brain, pancreatic and lung cancer, are 
still very low. Cancer has become the most important cause of death and morbidity in 
Europe after cardiovascular diseases.  
  The search for efficient anticancer drugs has been limited by the scarce understanding of 
cancer pathogenesis. Hence, preventive measures to reduce cancer incidence have strongly 
been advocated. Several researchers have been suggesting that some food-derived 
components exhibit potent inhibitory effects against cancers. If people could prevent the 
incidence of cancer by changing their diets, a great progress in medicine could be reached 
with enormous economic benefits. Among the most promising anticancer foods, milk is an 
essential part of diet in western life style. Current studies have provided enough evidences 
of the anticancer effects of milk-derived components including TRAIL (TNF-inducing 
apoptosis ligand), α-lactalbumin and lactoferrin. Today, technology is in place to enable the 
production of a great amount of potential anticancer agents from milk.  
   However, prior to clinical application of any drug, even if it is derived from natural 
sources, we need to figure out the mechanisms underlying its anticancer effects. Since 
2007, our group has been dedicated to the study of lactoferrin effects/roles on cancer, as 
well as its potential for cancer prevention and treatment. The study of the mechanisms 
underlying its inhibitory effects against cancers has been under investigation. Accordingly, 
this thesis aimed to unravel the mechanism involved in the lactoferrin effects against breast 
cancer cells. 
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                          CHAPTER 1  
General introduction  
 
Abstract 
Lactoferrin (LF) has been widely studied over the last 70 years and its role in diverse 
biological functions is well known and generally accepted by the scientific community. 
This protein is a key player in the human defense mechanisms against various diseases. 
The protein response elements have been localized and characterized. Usually, an 
alteration of the LF gene in cells is associated with an increased cancer incidence. Several 
studies suggest that exogenous treatment with LF and its derivatives can efficiently inhibit 
the growth of tumors and reduce cancer susceptibility. However, none of these studies 
reported a consistent outcome concerning the mechanisms underlying the anticancer 
effects of exogenous application of LF and its derivatives. In this chapter, the association 
of LF with cancer is thoroughly discussed from its gene expression to its potential use in 
cancer therapy. Furthermore, the LF cytotoxicity against several cancers is generalized into 
four possible mechanisms of action under different conditions: cell membrane disruption, 
apoptosis induction, cell cycle arrest and immunoreaction. Based on these mechanisms, 
new strategies to improve the anticancer effects of LF and/or its variants are proposed. 
Finally, the potential of LF in cancer therapy in the near future is discussed.  
 
 
 
 
 
 
 
Chapter 1 
4 
1.1 INTRODUCTION 
Lactoferrin (LF) is an 80 kDa glycoprotein comprised of a polypeptide chain containing 
703 amino acids. The single chain is folded into two homologous lobes in a higher 
structure, which are connected by a three-turn -helix [Farnaud＆Evans, 2003]. The two 
lobes bind and release iron by a substantial conformational change that contributes to the 
most important functions of the protein. LF can be found in mucosal secretions such as 
tears, saliva, bile, nasal and bronchial secretions [Rodrigues et al., 2009], and most 
abundantly in milk and colostrum [Masson＆ Heremans, 1971]. This wide distribution 
clearly demonstrates the important role of LF in the maintenance of homeostasis.   
Many relevant biological functions have been reported for LF, including anticancer, 
antibacterial, antiviral, antifungal, anti-inflammatory, and immune regulatory activities 
[Adlerova et al., 2008]. LF has also been suggested as a marker of active diseases [Gibson
＆Bowen, 2011]. Some studies support that LF‟s iron-binding ability and interaction with 
its specific receptors are the responsible for the diverse functions that have been 
demonstrated [Adlerova et al., 2008]. In addition, LF derived peptides, as well as the 
iron-saturated LF (holo-LF), have also been shown to be efficient anticancer and 
antibacterial drugs [Rodrigues et al., 2009]. However, the detailed mechanisms underlying 
the broad range of LF functions still need to be clarified. Though, regarding its role in 
cancer development and progression, a number of published data allows summing up the 
possible mechanisms of LF toxicity against cancer cells. For example, some studies 
showed that the downregulation or silencing of LF or delta LF (LF) genes in cells lead to 
an increase of malignant tumors [Benaïssa et al., 2010; Hoedt et al., 2010].
 
On contrary, 
the restoration of LF gene in cancer cells can efficiently block their proliferation [Breton et 
al., 2004; Zhou et al., 2008].
 
Additionally, several studies have shown that LF and/or its 
derivatives can inhibit the growth of tumors both in vitro and in vivo [Ushida et al., 1999; 
Sakai et al., 2005; Chandra et al., 2006; Onishi et al., 2008].  
Due to the considerable value that LF and/or its derivatives may have in cancer 
prevention and treatment, the present chapter aims to provide an overview of their 
mechanisms of action against cancer, as well as their possible future applications in 
therapy. 
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1.2 GENE STRUCTURE OF LACTOFERRIN  
LF gene has been localized at the chromosome level in a set of different species (human 
chromosome 3 and mouse chromosome 9) [Teng et al., 1987]. The full coding region of LF 
gene varies widely from 2055 to 2190 residues in different species due to the deletions, 
insertions and mutations that occur in the stop codon [Kang et al., 2008].
 
However, their 
transcripts are equally composed of 17 exons that are separated by introns ranging in size 
from 300 bp to 3.3 kb [Teng et al., 2002b] (Figure 1.1A).
 ΔLF was accidently discovered 
by positional cloning of the second breast cancer susceptibility gene (BRCA2) from a 
normal breast tissue [Siebert＆Huang, 1997]. It is the product of an alternative (P2) 
promoter present in the first intron of LF gene. As a result, ΔLF lacks the first 26 amino 
acids of the secreted LF. The P2 promoter activity can be dramatically enhanced with 
overexpression of the Ets-1 transcription factor [Liu et al., 2003].  
LF gene in the epithelium of the vagina and the isthmus oviduct is constitutively 
expressed but it is estrogen inducible in the uterus of immature mice and rats [Teng, et al., 
2002a]. In fact, LF mRNA synthesis is regulated either directly or indirectly by estrogen, 
retinoic acid, mitogen, and growth factors. The multiple response elements mainly lie in 
the three short, but complex, modules within 400 bp from the transcription site of LF gene 
[Teng et al., 2002b]
 
(Figure 1.1B). Two modules of the LF gene that respond to estrogen 
and growth factor stimulation have been distinctly characterized. The imperfect estrogen 
response element (ERE) is overlapped with a chicken ovalbumin upstream promoter 
transcription factor (COUP-TF), which acts as an estrogen-responsive negative regulator 
(Figure 1.1B). Overexpression of the COUP-TF expression vector can block the 
estrogen-stimulated responses [Liu et al., 1993].
 
The molecular mechanism of this negative 
regulation is attributable to the competition between COUP-TF and the estrogen receptor 
(ER) in the overlapping region. The human LF gene promoter (P1) contains two COUP-TF 
elements, one of which is overlapped with the ERE, while the other is present within a 
composite response element adjacent to the ERE [Teng, 1995] (Figure 1.1B). These 
complex modules contribute to the fine-tuning of estrogen regulation of LF gene 
expression. Steroid Factor 1 Response Element (SFRE), an additional element in the 
human LF gene, is located 26 bp upstream from the ERE and is also involved in estrogen 
responsiveness. Mutations at SFRE induce a 50% reduction of the activity of estrogen 
receptor  (ER). Also, the estrogen receptor-related receptor (ERR1) binding to SFRE 
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affects the transcriptional activity mediated by ER [Yang et al., 1996]. There are other 
types of ERE-negative regulatory factors, whose absence increases the expression of 
estrogen-induced LF by up to100-fold [Park et al., 2005].
   
The infection-responsive promoter in LF gene has also been characterized. 
Lipopolysaccharide (LPS)-responsive regions of the promoter contain one STAT3 site, 
three AP1 sites and eight nuclear factor κB (NF-κB) sites. LF promoter may respond to 
infections via the NF-κB site pathway [Zheng et al., 2005]. This observation explains the 
great increase of LF in the mammary secretions when infected by bacteria. The expression 
of LF is mainly stimulated by bacterial LPS and double-strand RNA (dsRNA) [Li et al., 
2009]. In addition, LF expression in mammary epithelial cells is mediated by changes in 
cell shape and actin cytoskeleton [Close et al., 1997]. Furthermore, miR-214, expressed in 
23 species, was found to be directly involved in the LF expression and the LF-mediated 
cancer susceptibility inmammary epithelial cells [Liao et al., 2010]. 
 
 
Figure 1.1 – Schematic representation of human LF gene. (A) Promoter and mRNA structure of human 
LF gene. The black arrows indicate the LF promoters (LF promoter and LF promoter). The translation 
start site and termination codon are marked with ATG and TAA, respectively. 1a stands for the first exon 
in LF, and 1b for ΔLF. The black bars and number indicate the exon size and location. (B) Diagram of 
response modules of human LF gene promoter. The numbers mean the position upstream from the start 
site of LF promoter 1. Overlapping regions between two different modules are illustrated using the 
DNA sequence [Yang et al., 1996; Liu et al., 2003].  
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Some of these response elements in the LF gene may be implicated in an increased 
cancer incidence, such as the estrogen and infection response elements. Estrogen can 
promote DNA synthesis and cell proliferation by turning on its responsive genes. Exposure 
to an excess of estrogen will greatly increase the incidence of breast cancers [Muti et al., 
2000; Kabat et al., 2006]. On the other hand, it is well known that one out of six cancers 
develops from infection [de Martel et al., 2012]. The module elements responding to the 
pathogenic factors are involved in the LF gene expression. This indicates that LF probably 
acts as a negative regulator in human body to repress the acute reaction to estrogen or to 
kill virus and bacterial infection by sharply raising the protein expression, which helps to 
decrease the cancer incidence. The full knowledge on these regulatory modules in the LF 
gene constitutes a powerful tool for designing novel strategies of cancer treatment.  
 
1.3 STRUCTURE AND PROPERTIES OF LACTOFERRIN AND 
ITS VARIANTS  
LF is a protein that is well-conserved among species [Gerstein et al., 1993]. It contains 
a simple polypeptide chain, which is folded into two symmetrically globular lobes 
representing the N- and C- lobes. The two lobes with 33-41% homologous sequences are 
connected by a short α-helix between the amino acids 333 and 343 [Masson＆Heremans, 
1971 ]. The interactions among the special hinge region mostly consist of hydrophobic 
effects which provide additional flexibility to the molecule. Both lobes are folded similarly 
including α-helix and β-pleated sheet structures, which are referred to as N1 and N2, or C1 
and C2. The iron binding site is located in the deep cleft of the two domains in each lobe 
and comprises four protein ligands: 2 Tyr, 1 Asp, and 1 His [Baker, 2009; 
González-Chávez et al., 2009) (Figure 1.2A). It can bind two ions of iron (Fe
2+
, Fe
3+
, Cu
2+
, 
Zn
2+
 and Mn
2+
) in the synergy with the carbonate ion (CO3
2-
), the iron saturation of which 
is named as holo-LF [Baker, 2009] (Figure 1.2B(a)). In addition, the other variant, apo-LF, 
results from the release of iron from LF (Figure 1.2B(b)). The two domains of each lobe in 
the holo-LF enclose the bound irons, which turns it a closed structure with greater 
resistance to proteolysis. In contrast, the apo-LF is more flexible due to the absence of a 
bound metal iron to lock the two domains of each lobe together [Gerstein et al., 1993; 
Baker, 2009]. 
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Figure 1.2 – LF structure. (A) Iron binding site. The four protein ligands (two Tyr, one Asp, one His) 
and the carbonate ion, together with the arginine residue and the N-terminus of helix 5, which help bind 
the carbonate ion, are shown for the N-lobe of human LF. Two basic residues after the iron site (here 
Arg210 and Lys301) help modulate iron release [Baker, 2009]. (B) Three-dimensional of bi-ferric LF. 
The N-lobe is on the left and the C-lobe is on the right, with the N- and C-terminus of the polypeptide 
chain labeled N and C. The four domains are labeled N1, N2, C1, C2, and the helix which joins the two 
lobes (H). The two iron binding sites are shown with red spheres. (a) Bovine lactoferrin 
[González-Chávez et al., 2009]. (b) Human lactoferrin [Baker, 2009].  
 
1.4 BIOLOGICAL FUNCTIONS OF LACTOFERRIN 
  LF plays an important role in the innate immunity, which responds to external 
stimulation in an antigen-nonspecific defense mechanism. For example, LF is massively 
released from neutrophils to blood and inflamed tissues when inflammation occurs 
[García-Montoya et al., 2012]. More important, LF exhibits strong inhibitory activity 
against a broad spectrum of bacteria, fungi, yeasts, virus and parasites 
[Rodrigues et al., 2009]. Moreover, other biological functions have been assigned to  LF, 
such as anticancer, hypoferremia and several enzymatic functions [Farnaud＆Evans, 2003] 
(Figure 1.3). 
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Figure 1.3 – The proposed roles of LF [Farnaud＆Evans, 2003]. 
 
LF extensive antimicrobial activities were generally attributed to its iron binding ability, 
which deprived the bacterium of iron [Adlerova et al., 2008]. However, some reports 
suggested that the LF bactericidal activities result from the direct interaction between the 
protein or its derived peptides and the bacterium [Legrand et al., 2008]. Besides, the 
mechanism underlying LF antiviral activity is determined by two different pathways: 
binding to viral particles and competing with virus-receptors in host cells [Farnaud＆Evans, 
2003]. The mechanisms involved in the other LF actions are also being investigated.  
 
1.5 GENETIC VARIATIION OF LACTOFERRIN GENE IN 
CANCER CELLS 
A relationship between LF expression and breast cancer susceptibility was first proposed 
by Furmansiki and collaborators [Furmanski et al., 1989]. They found that the 
LF-associated RNase activity was present at lower levels in the milk obtained from a 
consanguineous community with a high incidence of breast cancer in India. Recent studies 
also showed that both P1 and P2 promoter regions of the LF gene are downregulated or 
silenced in an extensive series of cancer cell lines [Hoedt et al., 2010]. This 
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downregulation is much more visible for △LF since its expression is either significantly 
diminished (BT-20 and MCF-7 cells) or practically absent (MDA-MB-231, T-47D and 
HBL 100 cells) [Benaïssa et al., 2005], but it is regularly expressed in normal tissues. 
Moreover, △LF stable expression or overexpression of LF resulted in a significant 
inhibition of cancer cells growth, as well as in a weaker in vivo formation potential 
[Breton et al., 2004; Zhou et al., 2008].  
Besides the distinct LF expression levels in normal or cancer tissues, the evaluation of 
the LF gene structure showed that the degree and pattern of methylation are notably altered 
in malignant breast cells [Panella et al., 1991; Teng et al., 2004]. For instance, an LF 
cDNA clone extracted from human breast tissues was used to evaluate the restriction 
fragment length changes and methylation patterns of DNA from normal peripheral blood, 
leukemia cells from patients, leukemia cell lines and breast cancer cell lines. Methylation 
patterns of DNA in malignant cells were highly variable and generally less methylated than 
in normal cells [Liu et al., 2002]. In addition, methylation assays conducted in a 
nasopharyngeal cancer (NPC) model demonstrated that the methylation also occurred in 
the promoter of the LF gene, which is linked with the decreased LF gene expression. 
Simultaneously, abnormal migration patterns of the LF gene were also found in cancer 
cells. More specifically, the alteration generally takes place in the LF exons 4, 5, 13, 14, 
and 15 [Luczak＆Jagodziński, 1990].  
Genetic variation of the LF gene significantly increases cancer susceptibility. The 
changes in methylation of the promoter or first exon may have the same impact as the 
effect of mutations of various tumor suppressor genes or proto-oncogenes. Carcinogenesis 
can result from aberrations in genomic DNA methylation, including hypermethylation and 
hypomethylation of the promoter or the first exon of cancer-related genes [Luczak＆
Jagodziński, 1990]. Recent studies show that, apparently, a relatively higher genetic 
polymorphisms, gene mutations, and promoter methylation in the LF gene occur in cancer 
cells [Panella et al., 1991; Liu et al., 2002; Teng et al., 2004]. All these observations 
suggest a close relationship between alterations of the LF gene and an increasing incidence 
of carcinomas. Hence, the use of LF as a novel cancer-specific marker may be useful for 
diagnosis and prognosis of cancer patients at different stages, or alternatively to be used as 
a therapeutic agent in the clinical practice. Since the recovery of LF expression 
successfully depresses the growth of tumors, the LF gene can be further explored as a new 
targeting site for cancer gene therapy.  
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1.6 ORAL ADMINISTRATION OF LACTOFERRIN REDUCES  
CANCER INCIDENCE 
To the best of our knowledge, there is no effective drug that can completely overcome 
cancer, especially for the patients at an advanced stage. This makes the prevention of 
carcinomas‟ development a crucial step for decreasing the high cancer mortality. Some 
epidemiological studies have shown that more than two-thirds of cancers could be 
prevented through the adoption of an appropriate lifestyle [Haque et al., 2010]. A diet 
regimen enriched in preventive agents is one of the proposals expected to decrease cancer 
incidence and other diseases [Cam＆de Mejia, 2012]. Milk-derived LF is a significant 
functional protein and reaches 7 g/L in colostrum [Masson＆Heremans, 1971]. The 
multifunctional LF could work as the “magic bullet” in cancer prevention.  
Indeed, a large number of reports provide clear evidences that the oral administration of 
LF can effectively decrease the development of chemically-induced cancers [Tanaka et al., 
2000; Tsuda et al., 2000; Chandra et al., 2006].
 
LF is a relatively stable protein that can 
survive even after transiting through the gastrointestinal tract as partially degraded 
fragments [Norrby et al., 2001; Teraguchi et al., 2004]. These fragments with a mass over 
20 kDa contain the receptor-binding regions, in addition to the anticancer active regions 
[Norrby et al., 2001]. An example of these fragments is the bovine lactoferricin B (LfcinB) 
peptide. Moreover, these fragments can be internalized by specific LF receptors in the 
intestinal brush border membrane [Suzuki et al., 2001]. The oral administration of 0.2% or 
2% bovine lactoferrin (bLF) was found to decrease by 32.5% and 42.5%, respectively, the 
occurrence of colon carcinogenesis in azoxymethane treated F344 rats [Tsuda et al., 2000]. 
In a study conducted with the 7, 12-dimethylbenz[a]anthracene (DMBA)-induced hamster 
buccal pouch (HBP) model, the incidence of carcinogenesis was efficiently reduced by 
dietary fed of 0.2% bLF [Mohan et al., 2006]. Also, oral administration of bLF was shown 
to have chemopreventive effects on tongue [Panella et al., 1991] esophagus and lung 
carcinogenesis in rats [Ushida et al., 1999]. The suggested chemopreventive effects could 
be due to the multiple LF-induced effects, including stimulation of the immune response 
[Tanaka et al., 2000; Tsuda et al., 2000], modulation of the carcinogen-metabolizing 
enzymes and oxidant-antioxidant profile in the target organs [Mohan et al., 2006], as well 
as inhibition of angiogenesis [Norrby et al., 2001]. The regulation of the immune function 
may be a key factor in the LF mechanisms of action that are involved in cancer 
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chemoprevention. Presently, the massive extraction of bLF is an industrial reality. 
Therefore, it is conceivable that in the near future people could take LF-contained pills or 
consume LF-enriched products to prevent cancer or delay its onset. 
 
1.7 MECHANISMS OF ACTION OF LACTOFERRIN AGAINST 
CANCER 
Although the exact mechanisms involved in the anticancer activity of LF are still unclear, 
they can be generally grouped into extracellular effects, intracellular effects, and 
immunostimulation. The LF extracellular effects are mainly related with its interaction 
with the cell membrane and membrane receptors [Yang et al., 2003; Arseneault et al., 
2010], while its intracellular effects suggested by most studies dominantly concerns cell 
apoptosis and cell cycle arrest (Table 1). The LF immunostimulation is primarily achieved 
by activating immune cells to release tumor cytotoxic effectors [Kuhara et al., 2000; Iigo et 
al., 2004; Fischer et al., 2006; WoLF et al., 2007]. The anticancer mechanisms of LF or its 
derivatives that have been proposed from in vitro experiments are diverse (Figure 1.4).  
 
1.7.1 TOXIC EFFECTS OF LACTOFERRIN AND ITS DERIVED 
PEPTIDES ON THE CELL MEMBRANE 
LF and its derived peptides were found to be easily internalized by cells [Rochard et al., 
1992; Bi et al., 1996]. LF enters cells via receptor mediated endocytosis in Jurkat human 
lymphoblastic T-cell line. Nevertheless, the efficacy of this uptake pathway is low [Bi et al., 
1996; Baumrucker et al., 2006]. On contrary, LF active peptide LfcinB exhibits higher 
conformation-dependent uptake efficiency [Duchardt et al., 2009]. Increased permeability 
may produce subtle changes in the membrane‟s barrier function that promote cell death. LF 
can increase cytolysis at a low concentration, while at a high concentration it modulates 
cytolysis depending on the target cell phenotype [Damiens et al., 1998]. Many studies 
demonstrated the presence of LF receptors on the tumor cell surface, such as heparan 
sulactoferrinate [Rochard et al., 1992; Bi et al., 1996; Baumrucker et al., 2006],
 
that when 
removed leads to a reduction of membrane binding and cellular uptake of LfcinB 
[Duchardt et al., 2009]. However, the characterization of these receptors is still under 
investigation because different cell types appear to express their own specific LF receptors.  
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Table 1. Mechanisms of action underlying the cytotoxicity of lactoferrin or its derived peptides against 
different cancer cells 
Action 
mechanism 
Cell lines  
Effective concentrations (μM) 
Ref 
bLF  hLF LfcinB 
Membrane 
Disruption 
Human neuroblastoma 
cell lines: Kelly, 
SK-N-DZ and IMR-32 
  12.8 Eliassen et al., 2006 
Human leukemia HL-60 
cells 
  *4-31.6 Onishi et al., 2008 
Cell cycle 
arrest 
Canine mammary gland 
adenocarcinoma cell 
lines: CIPp and CHMp 
0.32-6.41 
 
  Yamada et al., 2008 
Human breast cancer cell 
lines: MDA-MB-231 and 
MCF-7 
 0.625  Damiens et al.2008 
Human keratinizing 
squamous cell carcinoma 
(WHOI), CNE1 and 
undifferentiated 
carcinoma 5–8F and 
6–10B cells 
 10  Zhou et al., 2008 
Murine squamous cell 
carcinoma cell line: 
SCCVII and human 
cancer cell line: O12 
cells 
 250  WoLF et al., 2007 
Human head and neck 
cancer cell lines: 011, 
012, 019, and 022 
  10  Xiao et al., 2007 
Apoptosis 
Human stomach cancer 
cell line: SGC-7901 
50-100   Xu et al., 2010 
Human 
pheochromocytoma cells 
(PC12) 
 8.75  Lin et al., 2005 
Jurkat cells  8.75 64 Mader et al., 2005; 
Lee et al., 2009 
Human breast cancer cell 
line: MDA-MB-435 
  32-64 Furlong et al., 
2006; Mader et al., 
2005 
Human breast cancer cell 
line: MCF-7 
  7.5-64 Mader et al., 2005 
Human breast cancer cell 
lines: HS578T and 
T-47D 
 125   Duarte et al., 2001 
Human leukemia HL-60 
cells 
  **30-126 Onishi et al., 2008; 
Roy et al., 2002 
Human tongue-derived 
squamous cell carcinoma 
cell line: SAS 
   
640 
 
Sakai et al., 2005 
a). bLF, Bovine lactoferrin; hLF, Human lactoferrin; LfcinB, Bovine lactoferricin B. 
b).*L15 peptide (modified from Lfcin B14-31): P A WR K A R R WARR M K K L AA; **Lfcin17-38.  
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Figure 1.4 – Multiple signaling pathways potentially underlying the cytotoxicity of LF and its 
derivatives against cancers. 
 
LfcinB revealed a higher potential activity against tumor cells than LF. This may be due 
to the fact that it is a cationic antimicrobial peptide (CAPs). Some CAPs have shown a 
selective activity against cancer cells, thus constituting a promising group of novel 
anticancer agents with a new mode of action and broad spectrum of anticancer activity 
[Suzuki et al., 2001; Duchardt et al., 2009; Arseneault et al., 2010]. LfcinB is composed of 
25 amino acid residues (the residues 17-41 of bLF), containing a disulfide bridge between 
two Cys residues in positions 19 and 36 [Mohan et al., 2006; Liu et al., 2011] (Figure 1.5). 
This disulfide bond may not be essential in maintaining its antibacterial activity, but it is 
very important for the activity against tumor cells [Yang et al., 2002; Zhang et al., 2010]. 
In aqueous solution, the peptide loses the -helical portion of the parent protein, adopting a 
slightly twisted antiparallel β-sheet amphipathic structure, with nearly all the hydrophobic 
residues lining up on one face of the peptide [Zhou et al., 2004].
 
This change makes it bear 
similarities to several major classes of CAPs, which contain disulfide bridges and 
antiparallel β-stands, and form amphipathic helices upon binding to membranes . 
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Figure 1.5 – Structure of the LfcinB fragment. Crystal structure on the left and the NMR structure of 
the solution on the right. The β-sheet and α-helical structures are indicated by arrows and cylinders, 
respectively. The spheres highlight the two disulﬁde-linked Cys residues [Cam＆de Mejia, 2012]. 
 
Simultaneously, LfcinB exists as a -helix structure when it is still linked to the parent LF, 
and this is also an important feature of membrane-lytic peptides [Jin et al., 2005; 
Arseneault et al., 2010]. When CAPs come into contact with the cell membrane, 
conformational changes occur enabling their association with the membrane, and 
consequently the cell lyses [Jin et al., 2005]. It is important to notice that this mechanism is 
still not fully understood. However, the peptide-lipid interactions leading to membrane 
permeation play a major role in their activity [Arseneault et al., 2010].
 
Moreover, some 
CAPs can trigger apoptosis by disrupting the mitochondrial membranes [Ellerby et al., 
1999]. Fluorescence-labeled LfcinB has been found in the mitochondrial membrane of 
neuroblastoma cells [Eliassen et al., 2006]. Additionally, many studies suggest that the 
membrane may constitute one of the targets for the LF and LfcinB, through which they 
exert their anticancer effects [Mader et al., 2005; Mohan et al., 2006; Arseneault et al., 
2010].  
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1.7.2 CELL APOPTOSIS AND CELL CYCLE ARREST 
Cell apoptosis induced by LF and LfcinB has been described as the pivotal pathway by 
which they exert their cytotoxicity against various cancer cells. However, the apoptosis 
pathway that they trigger, extrinsic (Fas and other TNFR receptor family) or 
intrinsic (mitochondria-associated) pathway, apparently varies depending on the cell type 
used [Lin et al., 2005; Eliassen et al., 2006; Lee et al., 2009; Xu et al., 2010].  
Akt (protein kinase B) acts as an anti-apoptotic signaling molecule and it plays a critical 
role in the function of cancer cells [Testa＆Tsichlis, 2005]. For example, when stomach 
cancer cells SGC-7901 were treated with LF, the phosphorylated Akt and several key 
proteins involved in the signaling pathway were decreased, but expression of 
phosphorylated glycogen synthase kinase-3β (at Ser 256) and phosphorylated caspase-9 (at 
Ser 196) were increased, which suggests that the apoptosis of stomach cancer cell 
SGC-7901 induced by LF may be regulated via AKT pathway [Xu et al., 2010]. In addition, 
Akt can induce cell growth arrest by modulating the expression and activity of p21
Cip1
 and 
p27
Kip1 
[Damiens et al., 1999; Xiao et al., 2004].
 
After exposure to LF, the MDA-MB-231 
cells stopped at the G1 to S transition phase of the cell cycle, which was associated with a 
dramatic decrease in the levels of proteins Cdk2, cyclin E and Cdk4, accompanied by an 
augmented expression of the Cdk inhibitor p21
Cip1 
[Damiens et al., 1999].
 
Cell cycle arrest 
induced by LF was also demonstrated using NPC cells. The expression of cyclin D1 and 
phosphorylation of retinoblastoma protein (Rb) was downregulated, while expression of 
p21 and p27 was enhanced [Breton et al., 2004]. Furthermore, LF was also found to induce 
the mitogen-activated protein kinase (MAPK) pathway. For Jurkat T cells, the JNK (c-Jun 
N-terminal kinase) associated with Bcl-2 pathway is believed to be the pathway of 
LF-induced apoptosis. LF treatment induced the activation of caspase-9 and caspase-3 and 
increased the level of Bcl-2 phosphorylation. When JNK activation was abolished, 
LF-treated Jurkat cells did not undergo cell death [Lee et al., 2009]. Additionally, LF 
induced apoptosis in the colon mucosa of azoxymethane-treated rats by enhancing Fas 
expression. After oral administration of LF, the Fas protein expression was augmented 
more than 2.5 fold, and the active forms of both caspase-8 and caspase-3 were also higher. 
Immunohistochemical analysis revealed the presence of Fas-positive and apoptotic cells 
preferentially at the site of LF-mediated tumor inhibition [Fujita et al., 2004].
 
In addition, 
LF was found to protect PC12 cells from FasL-induced apoptosis at a low concentration 
(50 μg/ml), while it triggered apoptosis through regulation of the expression of 
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phosphorylated extracellular-signal-regulated kinase 1/2 (ERK1/2) at a high concentration 
(700 μg/ml) [Lin et al., 2005]. 
  Compared to LF, most studies with LfcinB demonstrate that cells undergo the 
mitochondrial-related apoptosis pathway [Mader et al., 2005; Eliassen et al., 2006; Onishi 
et al., 2008].
 
This may be due to its relatively higher efficiency of cell uptake [Bi et al., 
1996; Duchardt et al., 2009], which greatly facilitates its interaction with both surface 
death receptors and intracellular apoptosis-related proteins. An example includes the 
apoptosis induction in oral squamous carcinoma cells by JNK/SAPK activation using 
LfcinB. In the process, JNK pathway directly activates the mitochondrial death machinery 
[Aoki et al., 2002].  
 
1.7.3 IMMUNOSTIMULATION 
Immunostimulation is a key factor for the in vivo anticancer effects of LF. Both innate 
and adaptive immunity are involved in the LF or its derivatives induced immunoreaction 
[Kuhara et al., 2000; Iigo et al., 2004; Fischer et al., 2006; WoLF et al., 2007; Iigo et al., 
2009] (Figure 1.6). As a result of the cyclic change of LF concentration, the secretory 
components such as the immunoglobulin (Ig) A and IgG increase sharply at proestrous in 
the uterus and decline in the other stages [Kaushic et al., 1998]. In cancer cases, LF 
predominantly functions by activating a strong Th1 response and the release of anticancer 
killer cells [Fischer et al., 2006]. The recruitment of lymphocytes mainly including CD4+ 
and CD8+ reaches up to a 20-fold increase within treated animals after oral administration 
of bLF [WoLF et al., 2007]. The tumor-infiltrating lymphocytes can greatly inhibit the 
proliferation of cancers [June, 2007]. On the other hand, the expression of interferon-γ 
(IFNγ) [Iigo et al., 2009], caspase-1 and IL-18, IgM (+) and IgA (+) B cells are also 
significantly increased in the small intestine after bLF treatment [Wang et al., 2000; Artym 
et al., 2003]. Actually, a cascade effect exists among them. Caspase-1 is known to cleave 
pro-IL-18 to generate mature IL-18 [Iigo et al., 2004]. IL-18 is an IFN-γ 
production-inducing cytokine [Cao et al., 1999]. Further, IL-18 has an important role in the 
expression of TNF-γ in T cells and NK cells, and as a stimulator of TNF-α and several 
other cytokines. IL-18 can also enhance Th1 and NK cell responses and generate CD8+ 
effector T cells [Okamoto et al., 1999]. Systemic and intralesional administrations of IL-18 
significantly inhibited the growth of tumors [Cao et al., 1999]. In addition, LF can raise the 
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effector of NK cells and macrophages at low concentrations and enhance the production of 
nitric oxide that has been reported to sensitize tumors to chemotherapy [Damiens et al., 
1998; Kanwar et al., 2008]. Moreover, oral administrated bLF could systemically restrict 
VEGF165-mediated angiogenesis in rats [Norrby et al., 2001]. The combined effects of 
these factors succeed in eradicating tumors and blocking pathogens. However, LF iron-free 
(apo-LF) failed to restrain the growth of tumors [Wang et al., 2000]. LF can flexibly bind 
and release several kinds of iron related cations, such as Zn
2+
, Fe
3+
, Cu
2+
, Mn
3+
 and Ga
3+ 
[Adlerova et al., 2008]. Indeed, LF functions as one of the main iron regulators in human 
body and it is responsible for keeping the systemic iron homeostasis. The iron balance is a 
necessary factor for cell growth and enzyme activity. If unbalanced, iron can become a 
potentially toxic element, leading to the formation of free radicals. These radicals induce a 
cellular redox imbalance by producing oxidative stress, which may be related to oncogenic 
stimulation [Valko et al., 2006].
 
As such, LF may be an effective chelator to keep the 
balance of iron in vivo. Besides, iron chelators have been shown to possess 
antiproliferative activity both in vitro and in vivo [Richardson et al., 2009].
 
 
 
 
 
Figure 1.6 – Immunoreaction stimulated by LF or its derivatives in vivo. 
 
 
 
Chapter 1 
19 
1.8 ENHANCING THE ANTICANCER EFFECTS OF LACTOFERRIN  
AND ITS DERIVATIVES 
Currently, it is demonstrated and recognized that LF and its derivatives possess 
anticancer activities. However, their exclusive use in the clinical practice for cancer 
treatment has not provided the expected results. In contrast, their use in combination with 
other agents has proved to be highly well succeeded [Furlong et al., 2006; McKeown et al., 
2006; Massodi et al., 2009; Roseanu et al., 2010]. Therefore, it is expected that LF and its 
derivatives synergize with other known anticancer agents or delivery systems in order to 
promote their cytotoxicity against cancer.
 
The ability to specifically target a tumor is one of the desired properties of an ideal 
antitumor drug. An appropriate delivery system can be very helpful to target LF and its 
derivatives to the tumor. Massodi and co-workers [Massodi et al., 2009] developed an 
elastin-like polypeptide (ELP) carrier to deliver the peptide derivative of bLF. The 
thermally responsive assemblage is soluble in aqueous solutions at 37℃, but aggregates 
near 41℃, which makes it a perfect carrier for targeting solid tumors in which treatment is 
focused on hyperthermia. On the other hand, liposomes are an efficient drug delivery 
system and can greatly enhance the therapeutic potential of the encapsulated compounds. 
Liposome entrapped iron-free LF (apo-LF) clearly enhanced its inhibitory effect on the 
growth of B16-F10 cells [Roseanu et al., 2010]. In addition, a brain-targeted 
chemotherapeutical delivery system, doxorubicin-loaded LF-modified procationic 
liposome (DOX-LF-PCL), efficiently raised the uptake and cytotoxicity of LF against 
glioma C6 cells [Chen et al., 2011]. Furthermore, several studies successfully used 
adenovirus to target LF to cancers in animal models [Wang et al., 2011; Wang et al., 2012]. 
These recombinant adenoviruses could significantly suppress the growth of tumors by 
releasing LF within these solid tumors.  
The combination of LF or its variants with recognized anticancer agents is another 
effective pathway to increase their anticancer activities. Holo-LF fed tumor-bearing mice 
could completely eliminate their tumors with a single injection of known chemotherapeutic 
agents [Kanwar et al., 2008]. In vitro experiments showed that the cytotoxic effects of 
LfcinB were greatly augmented when added in combination with C6-ceramide and 
tamoxifen in breast cancer cells [Furlong et al., 2006]. Another interesting study revealed 
that a combination of human neutrophil peptide-1 (HNP1) and human LF could kill cancer 
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cells while sparing normal cells. Neither HNP1 nor human LF could individually 
demonstrate this effect [McKeown et al., 2006]. The selective cytotoxicity against cancers 
is the most important feature of any antitumor drug. Therefore, these successful case 
studies suggest that the combination of LF or its derivatives with other anticancer 
therapeutics could be an efficient way to boost their cytotoxicity, and consequently their 
performance against cancers.  
 
1.9 FUTURE TRENDS IN THE USE OF LACTOFERRIN FOR 
CANCER THERAPY 
  Although there is still some uncertainty on the mechanisms underlying the cytotoxicity 
of LF and its derivatives against cancer, there is no doubt about its potential anticancer 
activity. Being LF and its derivatives food-derived components, it confers an advantage 
regarding its potential use as a toxic-free drug for humans. Also, its stability through the 
gastrointestinal tract is beneficial if oral administration is envisaged. All these features are 
believed to be essential for an efficient drug. Nonetheless, so far there are no conclusive 
data that support the clinical application of this protein or its variants as a sole drug in 
cancer therapy. This is partly due to the paradoxical results from different reports, as well 
as due to the low cytotoxicity of LF and its derivatives against cancers from in vivo 
experiments. Additionally, immunoreaction stimulated by LF is thought to be a key factor 
in cancer therapy. Nevertheless, a considerable amount of in vitro data showed that LF and 
its derivatives could greatly restrain the proliferation of various cancer cells [Yang et al., 
2004; Mader et al., 2005; Duarte et al., 2011]. This means that their cytotoxicity probably 
is due to the direct contact between LF and cancer cells. Thus, the direct and indirect 
actions of LF should be fully explored to get a higher anticancer effect in vivo (Figure 1.7). 
The direct action of LF can be achieved by intratumoral or intravenous injection (i.v). 
Unfortunately, LF could be quickly cleared after i.v administration [Beljaars et al., 2002]. 
In that sense, perhaps a tumor-targeting delivery system is preferable to carry these 
proteins, which will prevent the protein from degradation before reaching tumor cells. 
Currently, several carrier vectors, systemic targeting or intracellular targeting, are available 
to deliver anticancer agents. Either widely used liposomes or rising nanoparticles have 
proved to be efficient carriers to be used in clinical practice. They may be modified with 
specific-ligands to target tumor cells, or just to stay longer in circulation, thus providing a 
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slow release of LF or its variants and so persistently activating the immune system. This 
approach will greatly reduce any possible adverse effects and will increase their 
performance against cancer. Also, the combination of LF and its derivatives with known 
anticancer drugs have shown their added value in cancer therapy and will continue to be 
further explored. In this approach, the very first use of LF in clinical practice will be as 
adjuvant in cancer therapy. This will not only take advantage of the immunotherapeutic 
effects of LF, but will also provide a higher anticancer effect as compared to the drugs‟ sole 
use. 
However, as previously discussed the best way to overcome cancers is to reduce the 
probability of their occurrence. LF has been proven to significantly decrease cancer 
incidence in vivo experiments [Iigo et al., 2004; Wolf et al., 2007]. Therefore, it is feasible 
to envisage a strategy in which LF can be supplied through diet as a food supplement that 
can be orally consumed to reduce cancer susceptibility. The oral administration of LF or its 
derived peptides seems to be an optimal way to prevent or cure gastrointestinal cancers 
without the occurrence of side effects. In addition, taking into account the strong 
immunostimulatory effects of LF against several cancers, it could play a key role in 
developing novel cancer vaccines.  
 
 
Figure 1.7 – Potential modes of application of LF and its derivatives for cancer prevention/therapy. 
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1.10 CONCLUSIONS 
  LF is a multifunctional protein that can be widely found in most mammalian cells. Its 
expression is regulated by several factors to maintain the homeostasis. Silencing or 
downregulation of the LF gene in cells usually is related with the occurrence of some 
diseases, namely with the incidence of carcinomas. Restoration of LF can effectively 
inhibit the proliferation of cancer cells. The response elements of diseases-related factors in 
the LF promoter and its adjacent regions could partly explain the vital role of this protein 
against chronic diseases. Cytotoxic assays also demonstrated the inhibitory effects of LF 
and its derivatives on the proliferation of multiple cancers, thus suggesting its potential in 
cancer prevention. However, the mechanisms involved in their cytotoxicity against cancer 
derived from in vitro experiments are not always conclusive. Fortunately, the conclusions 
drawn from in vivo experiments regarding the mechanisms involved are similar, i.e. tumors 
are eliminated due to the rise of tumor-killer cells that are stimulated by LF. However, the 
detailed action mechanisms underlying their anticancer effects still need to be further 
investigated. 
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CHAPTER 2 
Growth inhibitory potential of bovine 
lactoferrin and its variants against 
breast cancer cells 
 
Abstract  
Lactoferrin (LF) has long been known as a multifunctional protein and is still an interesting 
topic of research. Importantly, LF holds a great promise as a potential anticancer agent. 
Herein, we demonstrated that bovine lactoferrin (bLF) could efficiently inhibit the growth 
of T-47D, MDA-MB-231, Hs578T and MCF-7 breast cancer cells while showing very low 
effects against normal breast (MCF-10-2A) cells. Simultaneously, the variants of bLF were 
also found to inhibit the growth of breast cancer cells. Among them, holo-bLF (iron 
saturated) exhibited the highest anticancer effects. However, the bLF-derived peptides 
LfcinB17-41 and LfcinB26-36 showed low or no, respectively, growth inhibitory activity to 
the breast cancer cells. In addition, the bLF degradation test indicated that the protein is 
stable under the cell culture conditions, which excluded the possibility that its effects could 
be due to its degraded peptides. Furthermore, fluorescent-labeled bLF and LfcinB17-41 were 
found to internalize cancer cells and to remain in the cytoplasm. However, most bLF 
remained outside the cells, and therefore their effects may result from both the modulation 
of intracellular and extracellular (through receptor interactions) pathways. The results 
gathered in this work lay a solid foundation for studying the mechanisms of action 
underlying the growth inhibitory action of bLF against breast cancer. 
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2.1 INTRODUCTION  
Lactoferrin (LF), an 80 KDa protein with iron-binding ability, was first discovered in 
mammary secretions, but is synthesized by most mammalian tissues; it is present in high 
concentrations in human and bovine milk, but in lower concentrations in a variety of 
secretions derived from epithelial cells and the second granules of neutrophils [Tomita et 
al., 2002; Rodrigues et al., 2009; Tsuda et al., 2010]. Its expression is estrogen responsive, 
the LF mRNA and protein expression can be induced several hundred-fold in the 
reproductive organs by estrogen treatment [Teng et al., 2002a; Teng et al., 2002b]. In 
normal cycling women, LF gene expression in the endometrium increases during the 
proliferative phase and diminishes during the luteal phase [Teng et al., 2002b]. Indeed, 
there are two forms by which LF exists in the cell, secreted LF (LF) and cytosolic LF (△LF) 
that result from the use of alternative promoters: P1 for LF and P2 for △LF. Apart from the 
5‟ end, the △LF messenger is identical to the LF mRNA and translate from exon 1β leading 
to a protein devoid of a leader sequence and the first 25 amino acids [Siebert＆Huang, 
1997; Liu et al., 2003].  
The wide distribution of LF and its special gene structure suggest its crucial role in 
keeping homeostasis. In fact, previous studies demonstrated that LF is a multifunctional 
protein and shows a great amount of promising activities including antibacterial, antifungal, 
anti-inflammatory, antiviral, immunostimulation, among others [Adlerova et al., 2008]. 
Most importantly, the LF alteration in cells is closely related with the incidence of cancer 
[Siebert＆Huang, 1997; Hoedt et al., 2010]. For example, LF and ΔLF are significantly 
downregulated or silenced in an extensive series of cancer cell lines, especially in breast 
cancer cells [Benaïssa et al., 2005]. However, the recovery of LF or △LF could efficiently 
prevent the proliferation of cancer cells [Breton et al., 2004; Zhou et al., 2008]. Several in 
vitro and in vivo assays showed that LF and its peptides present a high potential as 
anticancer agents [Norrby et al., 2001; Roy et al., 2002; Teraguchi et al., 2004; Sakai et al., 
2005; Onishi et al., 2008]. The mechanism of LF action against cancer is not yet fully 
understood. The in vitro experiments showed that LF and its peptides inhibited the growth 
of cancer cells mainly by inducing cell cycle arrest and/or apoptosis [Damiens et al.,1999; 
Xiao et al., 2004; Mader et al., 2005; Eliassen et al., 2006; Furlong et al., 2006; Wolf et al., 
2007; Duarte et al., 2011]. Furthermore, it has been reported that orally administrated LF 
can survive the passage through the gastrointestinal tract as partially degraded fragments. 
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The remaining peptides rapidly lead to an increase of anticancer immune factors and 
decrease the development of chemically-induced cancers [Norrby et al., 2001; Teraguchi et 
al., 2004]. Although the mechanism underlying the LF and derived peptides cytotoxicity is 
still under investigation, its anticancer effect is beyond doubt. Indeed, many questions 
remain unsolved. For example, the possible internalization of LF by the cells and how fast 
this phenomena can occur. Some potential LF receptors and an indication of the LF 
internalization process have been reported in several cell lines [Rochard et al., 1992; 
Fillebeen et al., 1997]. However, more substantial evidences are required to support this 
conclusion. The elucidation of the LF internalization process will greatly contribute to 
understand the mechanism behind LF cytotoxicity against cancer.  
Based on the close relationship that has been reported between LF and breast cancers, 
this work aims to comprehensively evaluate the cytotoxicity of bovine lactoferrin (bLF) 
and its derivatives on normal and breast cancer cells. The results will clarify whether bLF 
has a selective cytotoxicity to cancer cells and also what is the range of concentrations to 
be further tested for clinical therapy. Additionally, since a great amount of studies suggest 
that bLF-derived peptides also have high cytotoxic effects to cancer cells [Roy et al., 2002; 
Sakai et al., 2005], we will evaluate the possibility that the bLF cytotoxicity against cancer 
could be due to its degraded peptides. For that purpose, the degradation of the protein 
subjected to cell culture conditions will be studied. Furthermore, the internalization of bLF 
and LfcinB will be assessed.  
 
2.2 MATERIALS AND METHODS  
2.2.1 Cell lines 
T-47D and MDA-MB-231 breast cancer cell lines were kindly provided by IPATIMUP 
and Medical School from University of Porto (Portugal), respectively. The T-47D cell line 
was established using a pleural effusion of a 54 year old female patient with an infiltrating 
ductal carcinoma of the breast and is positive for estrogen receptor (ER+). The 
MDA-MD-231 epithelial cell line was established from a pleural effusion obtained from a 
51 year old female patient with breast cancer and is estrogen receptor-deficiency. Hs578T 
cells were kindly provided by Life and Health Sciences Research Institute, University of 
Minho (Portugal). These are fibroblastic cells established from breast tissue of a 74 year 
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old female patient. MCF-7 and MCF-10-2A were purchased from the American Type 
Culture Collection. The MCF-7 epithelial cell line was established using a pleural effusion 
of a 69 year old female patient with adenocarcinoma. MCF-10-2A is epithelial cell from 
normal breast tissue. The cancer cells (T-47D, MDA-MB-231, Hs578T and MCF-7) were 
cultured in L-glutamine-containing DMEM medium (Biochrom AG, Berlin, Germany) 
supplemented with 10% fetal bovine serum (Biochrom AG), 100 U/ml 
penicillin/streptomycin (Sigma-Aldrich, Steinheim, Germany) at 37℃ in a humidified 
incubator with a 5% CO2 atmosphere. MCF-10-2A was cultured in DMEM/F12 medium 
(Biochrom AG) supplemented with 20 ng/ml epidermal growth factor (Gibco), 100 ng/ml 
cholera toxin (Sigma-Aldrich), 0.01 mg/ml insulin (Sigma-Aldrich) and 500 ng/ml 
hydrocortisone (Sigma-Aldrich), and 5% horse serum (Biochrom AG) in the same 
incubator as the cancer cells.  
 
2.2.2 Lactoferrin 
Bovine lactoferrin was bought from the company DMV (Veghel, The Netherlands). The 
purity of the protein is about 80% with 3.5% moisture, and its iron content is around 120 
ppm (0.12‰). In other words, the iron saturation of the bLF is 21% iron-content. Purer 
bLF (≥85%) was purchased from Sigma-Aldrich (Sigma-Aldrich); and peptides, 
LfcinB26-36 (lactoferricin B, fragment 4-14 trifluoroacetate salt) and LfcinB17-41, were 
bought from Sigma-Aldrich and AnaSpec (Catalog #62651) companies, respectively. 
Except for the fluorescence-labeled experiment in which the higher purity bLF was used, 
all the other experiments were conducted with bLF from the company DMV. The peptides 
sequences are described in detail below: 
LfcinB26-36: Arg-Arg-Trp-Gln-Trp-Arg-Met-Lys-Lys-Leu-Gly (Purity ≥95%). 
LfcinB17-41: H - Phe - Lys - Cys - Arg - Arg - Trp - Gln - Trp - Arg - Met - Lys - Lys - Leu - 
Gly - Ala - Pro - Ser - Ile - Thr - Cys - Val - Arg - Arg - Ala - Phe - OH (S - S BOND) 
(Purity ≥95%). 
 
2.2.3 Preparation of iron-free and iron-saturated lactoferrin 
2.2.3.1 Iron-saturated lactoferrin (holo-bLF) 
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FeCl3.6H2O was dissolved in 0.1 M NaHCO3, buffered with 0.1 M sodium citrate at pH 
8.0 to obtain a concentration of 20 mM. Meanwhile, bLF was dissolved using the same 
reagent/buffer to obtain a concentration of 1 mM. Next, both solutions were mixed together 
by 1:1 and equilibrated for 24 h at room temperature, followed by extensive dialysis 
against 1 L of 0.1 M sodium bicarbonate to remove free metal ions for 24 h with four 
bicarbonate changes at 4℃. At last, holo-bLF powder was obtained by freeze-drying [Li et 
al., 2009].  
 
2.2.3.2 Iron-free lactoferrin (apo-bLF) 
Apo-bLF was prepared by dialysis of a 1% bLF solution in water against 30 volumes of 
0.1 M citric acid, pH 2.3, containing 500 mg/L di-sodium EDTA, for 30 h at 4° C. Citrate 
and EDTA were then removed by dialysis against 30 volumes of ultrapure water at 4℃ for 
48 h with four water changes. The solutions containing apo-bLF were freeze-dried 
[Kanwar et al., 2008]. 
The iron content in holo-bLF and apo-bLF was determined by spectroscopy. The ratio of 
A475 nm/A280 nm should be routinely around 0.004 and 0.002 for holo-bLF and apo-bLF, 
respectively [Hashizume et al., 1987]. 
 
2.2.4 MTS assay 
Cells at exponential phase were trypsinized and seeded in a 96-well-plate in a volume of 
100 µl per well. After 12 h of incubation, the media were replaced with fresh medium 
containing bLF or its variants at different concentrations. All the stocks of bLF and its 
variants were prepared by dissolving them in phosphate buffered saline (PBS), respectively. 
The low range concentrations of bLF were set up at 0.25 μM, 0.5 μM and 1 μM, while the 
high range concentrations were 1.875 μM, 3.75 μM, 7.5 μM, 15 μM and 30 μM. The cells 
were incubated with the bLF for 24 h, 48 h or 72 h. At the defined time points, cell 
viability after treatment with bLF was evaluated using the MTS reagent kit (3-(4, 
5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) 
according to the manufacturer guidelines (Promega, Madison, USA). The results of cell 
viability were recorded at 490 nm using a spectrophotometer. The ability of bLF and its 
derivatives to inhibit the growth of breast cancer cells were calculated according to the 
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absorbance values of samples relative to the control (cells incubated with PBS instead of 
bLF). Each experiment was repeated at least three times.      
 
2.2.5 Lactoferrin degradation assay 
For the degradation assay, 15 μM bLF was incubated with cells in a 96-well-plate for 24 
h, 48 h or 72 h under cell culture conditions (DMEM media with 10% FBS, 37℃, 80% 
humidity and 5% CO2). Afterwards, the media were centrifuged to remove cells, and equal 
volume of supernatant from each well was analyzed using 10% SDS-PAGE or 
Tricine-SDS-PAGE to find the possible degradation of bLF under cell culture conditions. 
Simultaneously, bLF dissolved in PBS, DMEM and DMEM with 10% FBS without 
incubation in incubator was used as the control. Proteins in the SDS-PAGE and 
Tricine-SDS-PAGE were visualized by Coomassie blue or silver staining [Schägger, 2006]. 
 
2.2.6 Possible uptake of lactoferrin by cells  
The disappearance of LF from extracellular medium visualized by SDS-PAGE was used 
as an indirect indication of LF internalization. For that, a certain number of T-47D cells 
(10000 cells/well) and MDA-MB-231 (6000 cells/well) or a gradient number of T-47D 
cells (1200, 6000 and 30000 cells per well) were seeded in a 96-wellplates. 24 h after 
plating, 3.75 μM bLF was added and incubated with cells, and at a fixed times (24 h, 48 h 
or 72 h), medium was collected and centrifuged to remove the floating cells. Equal volume 
of the supernatants was analyzed by 10% SDS-PAGE as described above. 
 
2.2.7 Protein/peptide labeling 
The bLF with high purity (≥85%) was dissolved in PBS to get to 1 mg/ml, which is the 
optimal labeling concentration according to the supplier instructions for the CF
TM
568 
succinimidyl ester labeling kit (Sigma-Aldrich). The bLF solution was mixed with 
pre-warmed 10× Mix-n-stain reaction buffer at a ratio of 1:10. The mixture was totally 
transferred to the CF™568 succinimidyl ester-containing vial and was further mixed in a 
vortex for a few seconds and incubated in the dark for 30 min at room temperature. The 
final concentration of CF dye-staining bLF solution reached up to 11.25 μM and was then 
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stored at -20℃.   
LfcinB17-41 peptide was labeled using the same procedure as the one above described for 
bLF. Due to the low molecular weight of the peptide [Roy et al., 2002], the final 
concentration of labeled LfcinB17-41 was 213 μM. 
 
2.2.8 Cell internalization of lactoferrin and peptides - confocal analysis 
Cells seeded overnight on glass coverslips at 37℃ under 5% CO2, were rinsed with 
fresh medium and incubated at 37℃ for 30 min, 1 h or 2 h in pre-warmed medium 
containing fluorescence–labeled bLF (1.406 μM) or LfcinB17-41 (10.65 μM) in a 
24-well-plate. After incubation, the coverslips were rinsed 3× with PBS, fixed in 4% 
paraformaldehyde for 10 min, and washed 3× in PBS. The coverslip was carefully moved 
to the slides and covered with one drop of Hoechst (0.5 μg/ml) for 15 min in a dark place 
to counter stain nuclei. Next, the Hoechst was removed and a small drop of mounting 
media (Glycerol-antifade) was placed on the coverslip. Cellular uptake and distribution 
were photographed using an inverted confocal laser scanning microscope (Olympus 
BX61/FLUOVIEW100). Subsequently, the photos were processed by the software of 
Olympus Fluoview version 3.0.  
 
2.2.9 Statistical analysis 
Student‟s t test was used in this study to determine the statistical significance of the 
experimental results. For p-values below 0.05 the differences between experimental groups 
were considered significant. 
 
2.3 RESULTS 
2.3.1 Growth inhibitory effects of lactoferrin against breast cancer cells 
In this study, growth inhibition ability of bLF against the breast cancer cells T-47D, 
MDA-MB-231, Hs578T and MCF-7 was evaluated by the MTS assay. The results showed 
that bLF could effectively inhibit the growth of all breast cancer cells studied in a 
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concentration- and time-dependent manner (Figure 2.1A). At the highest concentration, the 
inhibitory rates of bLF at the tested concentrations against T-47D, MDA-MB-231, 
Hs-578T and MCF-7 exceed by far 50% after 72 h of treatment (Figure 2.1B). The four 
cancer cell lines are representative of different genetic backgrounds (e.g. T-47D and 
MCF-7 are estrogen-receptor-positive (ER+), while there are no estrogen receptors (ER-) 
in MDA-MB231 and Hs578T [Mercatante et al., 2002; Zhuang et al., 2008]). However, it 
was clearly seen that bLF displayed similar growth inhibitory effects on all of them. These 
results suggest that bLF could be used as a broad-spectrum anticancer agent in cancer 
therapy, at least for several types of breast cancers. In addition, selectivity is always a 
desired property of any effective anticancer drug. Therefore, the effect of bLF against 
MCF-10-2A, a normal breast cell line, was also evaluated in the current work. The results 
demonstrated that bLF possess a much less pronounced growth inhibitory effect on normal 
cells as compared to the cancer ones (Figure 2.1C). The inhibitory rate was less than 25% 
after 48 h treatment even for the highest concentration of bLF, while for the breast cancer 
cells it totally surpassed 40% (Figure 2.1A＆C). In summary, the results indicated that 
bLF broadly inhibited the growth of breast cancer cell lines (T-47D, MDA-MB-231, 
Hs578T and MCF-7), while it only slightly affected normal cells, and therefore could be 
considered as a potential selective anticancer drug.  
 
2.3.2 Growth inhibitory effects of lactoferrin variants 
Holo-bLF and apo-bLF were prepared by adding or removing Fe
3+ 
from bLF using 
well-known reported methods [Kanwar et al., 2008; Li et al., 2009]. The holo-bLF was 
found to be a red powder and the bLF was yellowish. Apo-BLF was a white powder since 
the colored reagent in bLF, Fe
3+
, was removed (Figure 2.2A). The spectroscopy analysis 
showed that the ratio A475nm/A280nm was around 0.004 for holo-bLF and 0.002 for 
apo-bLF. These results confirmed that the iron content of holo-bLF and apo-bLF was 
around 100% and 0%, respectively [Hashizume et al., 1987].  
The bLF cytotoxicity against several cancers has been widely shown in the literature 
[Roy et al., 2002; Teraguchi et al., 2004; Onishi et al., 2008]. However, there are few 
reports concerning its derivatives, namely with different iron contents (e.g. holo-bLF, 
apo-bLF) or its peptides (e.g. LfcinB26-36 and LfcinB17-41), especially regarding its activity 
against breast cancer cells. Therefore, the goal of this experiment was to compare the  
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Figure 2.1 – Cytotoxicity of bLF against T-47D, MDA-MB-231, Hs578T, MCF-7 and MCF-10-2A cell 
lines. Cells were seeded in 96-well-plate and treated with bLF for 24 h, 48 h or 72 h. After exposure to 
bLF, cell viability was evaluated by the MTS assay. Results correspond to the mean ± SD of three 
independent experiments. Statistical significance of differences between treated and non-treated groups 
is given by the p-values; *p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001. (A) Cell viability of 
T-47D, MDA-MB-231, Hs578T and MCF-7 breast cancer cells. (B) Half maximal growth inhibitory 
concentration (GI50) of bLF on the viability of T-47D, MDA-MB-231, Hs578T and MCF-7 cells. (C) 
Cell viability of normal breast cancer cells MCF-10-2A after a 48 h exposure to bLF.      
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anticancer potential between bLF and its variants against several breast cancer cell lines. 
Cell viability was determined by the MTS assay after treating cells with bLF, holo-bLF, 
apo-bLF and LfcinB26-36 and LfcinB17-41 at 15 μM for 48 h. Figure 2.2B clearly 
demonstrated that bLF, holo-bLF, apo-bLF and LfcinB17-41 limited the proliferation of 
breast cancer cells. However, LfcinB26-36 did not exert any growth inhibitory effect on 
these cells. Among the bLF derivatives, holo-bLF showed the highest anticancer potential. 
Also, the inhibitory rate of bLF was higher than that of apo-bLF on MDA-MB-231 and 
Hs578T cells. The bLF-derived peptides, in particular the peptide LfcinB17-41 was expected 
to show higher anticancer potential than the protein itself since it is a cationic antimicrobial 
peptide [Yang et al., 2003] and exhibits a high conformation-dependent uptake efficiency 
[Duchardt et al., 2009]. However, the peptides showed lower or no inhibitory effects on the 
growth of cancer cells. Comparing both peptides, it is possible to see that LfcinB26-36 
sequence is included within the LfcinB17-41, but it lacks a disulfide bond [Freiburghaus et 
al., 2009]. This suggests that the growth inhibitory effect observed for LfcinB17-41 could be 
partly due to the chemical bonding. Indeed, this has been demonstrated to be a key factor 
for the functioning of the peptides [Yang et al., 2002; Zhang et al., 2002].  
 
Figure 2.2 – Effect of bLF, holo-bLF, apo-bLF, LfcinB26-36 and LfcinB17-41 on the viability of T-47D, 
MDA-MB-231, Hs578T and MCF-7 cells. (A) Holo-bLF, bLF and apo-bLF powder appearance. (B) 
Viability of T-47D, MDA-MB-231, Hs578T and MCF-7 cells after treatment with bLF, holo-bLF, 
apo-bLF, LfcinB26-36 and LfcinB17-41 at 15 μM for 48 h. Results are expressed as mean ± SD of three 
independent experiments (*p-value < 0.05, **p-value < 0.01 in paired t-test).  
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2.3.3 Lactoferrin, apo- and holo- lactoferrin at low range concentrations 
still inhibited the growth of breast cancer cells 
As the above results showed, bLF presented obvious growth inhibitory effects on the 
studied breast cancer cells at high concentrations. However, some studies had indicated 
that LF as a food-derived protein could stimulate the growth of cells [Naot et al., 2005; Lee 
et al., 2009]. Therefore, in this experiment we investigated whether bLF could promote the 
proliferation of cancer cells at low concentrations. Our results demonstrated that bLF, 
holo-bLF and apo-bLF inhibited the growth of T-47D (Figure 2.3A) and 
MDA-MB-231(Figure 2.3B) cells at the concentrations of 0.25 μM, 0.5 μM and 1 μM. 
Although the inhibitory effects at the low concentrations were weaker than the ones 
observed for the high range of concentrations, these results suggest that bLF and its 
variants (holo-bLF and apo-bLF) do not promote the proliferation of cancer cells, at least 
of T-47D and MDA-MB-231 cancer cells.  
 
2.3.4 Lactoferrin stability under cell culture conditions 
Several studies have demonstrated the cytotoxicity of LF against various cancers
[Damiens et al., 1999; Xiao et al., 2004; Furlong et al., 2006]. However, the possibility 
that LF anticancer effects could result from its major digested peptides have not been 
 
 
Figure 2.3 – Effect of bLF, holo-bLF and apo-bLF at low concentrations on the cell viability of T-47D 
and MDA-MB-231 cells. Cells were treated with bLf at 0.25 μM, 0.5 μM and 1 μM for 48 h and cell 
viability determined by the MTS assay. Results represent the mean ± SD of three independent 
experiments. No statistical significant differences were found among the different groups. 
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excluded. In fact, we demonstrated above that LfcinB17-41 still possesses growth inhibitory 
activity. Therefore, the aim of this experiment was to study the possible degradation of bLF 
when subjected to cell culture medium and cell culture conditions. For that purpose, 15 μM 
bLF was incubated with T-47D and MDA-MB-231 cells, and culture medium collected at 
fixed time points to infer about the presence of bLF protein/peptides by SDS-PAGE. To 
find the potential bLF-derived peptides, 8 μg of bLF (calculated from the amount that was 
dissolved in the medium at the beginning of the assay) was loaded into each well of the gel. 
Coomassie blue staining did not show any distinct bands after bLF incubation with cells as 
compared to control groups (bLF in PBS, DMEM and DMEM with 10% FBS) (Figure 
2.4A). No pronounced bands corresponding to bLF degradation (≥ 25 KDa) under cell 
culture conditions could be observed, thus suggesting that the observed activity against 
cells might be due to the protein itself. 
Until now, the published reports on functional bLF-derived peptides regard the 
LfcinB17-41 [Roy et al., 2002; Onishi et al., 2008]. The molecular weight of this peptide is 
3.1239 KDa. Tricine SDS-PAGE is a useful method to detect low molecular weight 
proteins or peptides. To find small bands corresponding to potential digested peptides from 
bLF, a high concentration of bLF (320 μg) was loaded into each well of a Tricine 
SDS-PAGE gel after incubation with cells. However, using the Coomassie staining method 
it was not possible to observe different bands compared with the control groups (Figure 
2.4Ba＆b). Therefore, the more sensitive silver staining method was used. Nevertheless, 
still no obvious differences could be observed between the experimental and control 
groups (Figures 2.4Bc＆ d). Non-specific bLF bands were observed both in the 
experimental and PBS groups. This was mainly due to the low purity of the bLF used 
(about 80%). In summary, these results demonstrated that bLF was an extraordinarily 
stable protein when incubated up to 72 h in culture medium with T-47D and 
MDA-MB-231 cells at 37℃ in a humidified incubator with a 5% CO2 atmosphere. 
Furthermore, the results also suggest that the bLF growth inhibitory effects against cancer 
cells are due to the presence of the protein itself, rather than from the possible bLF-derived 
peptides.  
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Figure 2.4 – bLF degradation assay. (A) bLF was incubated with cells (T-47D and MDA-MB-231) for 
24 h, 48 h and 72 h under cell culture conditions. Medium samples containing bLF were loaded in 10% 
SDS-PAGE and proteins were visualized by Coomassie blue staining. (B) bLF degradation assay by 
Tricine-SDS-PAGE. Cells were treated with bLF for 24 h, 48 h and 72 h. Medium samples containing 
bLF were loaded in Tricine-SDS-PAGE gels and proteins were visualized by Coomassie blue (a, b) and 
silver staining (c, d), respectively. Shown gels are representative of threeindependent experiments. 
 
2.3.5 Lactoferrin was not significantly internalized by T-47D and 
MDA-MB-231 cells 
The previous results had shown the inhibitory effects of bLF on the proliferation of 
T-47D and MDA-MB-231 cells. According to some reports, bLF mainly exerts its 
anticancer effects by binding to specific receptors on the cell surface [Rochard et al., 1992; 
Fillebeen et al., 1999]. Therefore, in this experiment we aimed to evaluate if cells could 
uptake large amounts of bLF from the culture medium. A 0.2 μg bLF (calculated from the 
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added bLF concentration at the beginning of the assay) amount from the each sample after 
incubation under cell culture conditions was loaded onto an SDS-PAGE gel. By loading 
low amounts of bLF in the gel it is expected to be easier to find noticeable differences of 
protein content among the groups in which bLF was incubated with the same number of 
cells for different times, or with different number of cells at the same time point. However, 
no changes in the amount of protein band corresponding to bLF could be found neither for 
different incubation times (Figure 2.5A) nor for an increased number of cells (Figure 
2.5B). These results showed that bLF mainly stays outside the cell, but it cannot be 
excluded the possibility that a small amount of bLF could still be internalized by cells.   
 
 
Figure 2.5 – Study of the potential uptake of bLF by T-47D and MDA-MB-231 cells. bLF was 
incubated with the same number of cells for 24 h, 48 h and 72 h (A) or with different number of cells for 
24 h (B). At a given time point, bLF in the medium was analyzed by SDS-PAGE and stained with 
Coomassie blue. Shown gels are representative of three independent experiments. 
Chapter 2 
47 
2.3.6 Dye-labeled lactoferrin is rapidly internalized by T-47D and 
MDA-MB-231 cells 
The SDS-PAGE assay showed that bLF (80 KDa) was “blocked” outside the cell 
membrane. Indeed, it is not expected that such a big protein could be considerably 
internalized by cells. In order to confirm this assumption we performed an internalization 
assay using the protein labeled with a fluorescence dye. The results showed that bLF could 
enter inside T-47D (Figure 2.6A) and MDA-MB-231 (Figure 2.6B) cells after 1 h 
incubation and that it accumulates in vesicle-like structures. However, it was found that 
bLF stays in the cytoplasm and does not enter the nucleus (Figure 2.6). These results 
indicated that an intracellular pathway may be involved in the anticancer effects of bLF. 
 
2.3.7 LfcinB17-41 is quickly internalized in T-47D, MDA-MB-231, Hs578T 
and MCF-7 cells 
In the previous section we demonstrated that bLF could enter cells but it did not 
penetrate the nuclear membrane. LfcinB17-41 is a cationic antimicrobial peptide (CAPs) 
with small molecular weight. These peptides have been shown to have specific 
membrane-disruption ability [Onishi et al., 2008]. As such, it is expected that it could 
penetrate cells and also enter the nucleus. Therefore, we evaluated this possibility by 
incubating the labeled LfcinB17-41 with T-47D, MDA-MB-231, Hs578T and MCF-7 cells 
for 30 min and 2 h. The final concentration of the labeled peptide in the medium was 10.65 
μM. The results demonstrated that LfcinB17-41 could rapidly internalize cells after 30 min. 
However, the peptide remained in the cytoplasm even after 2 h incubation and we could 
not observe the peptide entering the nucleus in any of the four cell lines studied 
(Figure2.7). 
 
2.4 DISCUSSION  
In this chapter, we successfully assessed the inhibitory effects of bLF on the growth of 
four breast cancer cell lines under study (T-47D, MDA-MB-231, Hs578T and MCF-7). 
bLF could effectively inhibit the growth of all cancer cell lines, while showing a low effect 
against the normal breast cells. Simultaneously, we demonstrated that bLF variants with  
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Figure 2.6 – bLF internalization by T-47D and MDA-MB-231 cells. Evaluation of Alexa Fluor 
568-labeled bLF penetration into T-47D (A) and MDA-MB-231 (B) cells after 1 h incubation at 37℃ 
and 5% CO2. Red, Alexa Fluor-labeled bLF; blue, Hoechst-stained nucleus.  
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different iron contents (holo-bLF and apo-bLF) limited the proliferation of cancer cells. 
Some studies indicated that holo-bLF presented higher anticancer effects than bLF and 
apo-bLF on the inhibition of tumors in vivo [Kanwar et al., 2008; Sun et al., 2012]. Herein, 
we also found that holo-bLF exerted the highest growth inhibitory effect on the breast 
cancer cells as compared with bLF and its other derivatives (apo-bLF, LfcinB26-36 and 
LfcinB17-41). Iron-saturation does not lead to special conformational changes in the 
holo-bLF form except for a “closed” and stable structure when compared with apo-bLF 
free-iron form [Baker EN＆Baker HM, 2009]. In contrast, the apo-BLF structure is more 
flexible, and its fully open structure helps it to easily incorporate metal iron in its binding 
sites [Baker EN＆Baker HM, 2009]. Therefore, the structure differences may not explain 
their distinct functional activities. Additionally, the iron deprivation from cell culture 
medium should not account for their cytotoxicity because holo-bLF (100% iron saturation) 
was more active than bLF (21% iron saturation) and the apo-bLF (0% iron saturation). This 
indicates that iron content may be responsible for the discrepancy in their anticancer 
activity against the breast cancer cells. For example, its possible degradation inside the cell 
may release free iron in quantities that will be toxic for the cells due to promotion of 
generation of reactive oxygen species. However, it cannot be the sole explanation since 
even the apo-bLF has significant growth inhibitory activity of the breast cancer cells. 
 Some studies have reported that bLF can act as a growth stimulant for some cell lines 
at low concentrations [Naot et al., 2005; Lee et al., 2009]. However, bLF at the 
concentrations of 0.25 μM (20 μg/ml), 0.5 μM (40 μg/ml) and 1 μM (80 μg/ml) still could 
inhibit the growth of breast cancer cells. Likewise, the bLF-derived peptides had also been 
demonstrated to be cytotoxic to cancer cells [Sakai et al., 2005; Eliassen et al., 2006; 
Furlong et al., 2006]. Therefore, we hypothesized that the bLF cytotoxicity could have 
been generated from its degraded peptides under cell culture conditions, since these 
conditions as well as the presence of enzymes potentially released by cells could lead to 
protein degradation. However, our results from the SDS-PAGE and Tricine-SDS-PAGE 
experiments could not evidence the presence of any peptides potentially degraded from 
bLF. This result confirmed that bLF is a very stable protein even under cell culture 
conditions. As such, the question on how such a big protein exerts its effects against cancer 
cells, through intracellular or extracellular pathways, remained unclear. Our study showed 
that at 15 μM most of bLF stayed outside cells, although some fluorescent-labeled bLF 
could internalize the cells. LfcinB17-41 peptide was supposed to be internalized by the 
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nucleus because of its cationic peptides property [Potocky et al., 2003]. However, similarly 
to bLF, we only observed the peptide in the cytoplasm and frequently accumulated in 
vesicle-like structures. Therefore, the internalization results suggest that the bLF anticancer 
effects may be due to both the modulation of intracellular and extracellular (effects 
mediated by membrane receptors) targets. Although the protein and its peptide (LfcinB17-41) 
were rapidly internalized by the cells, most of bLF was still in culture medium after 72 h, 
and therefore, it cannot be excluded that its anticancer effects is potentially mediated in the 
extracellular milieu by its role in adjusting cell microenvironment or modulating cell 
receptors-mediated signaling. 
Contrarily to most LF-related studies that are only focused on LF or one of its variants 
 
 
Figure 2.7 – Internalization of LfcinB17-41 by breast cancer cells. LfcinB17-41 labeled with Alexa Fluor 
568 was incubated with T-47D, MDA-MB-231, Hs578T and MCF-7 cells at 37℃ and 5% CO2 for 30 
min and 2 h. Red, Alexa Fluor-labeled bLF; blue, Hoechst-stained nucleus.  
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[Damiens et al., 1999; Onishi et al., 2008], the current work was the first report on the 
systematic evaluation of the growth inhibitory effects of bLF and its variants against 
multiple breast cancer cell lines. Moreover, a normal human breast cell line, MCF-10-2A, 
was also used to evaluate the selectivity of bLF, a control procedure that was almost 
omitted in previous LF studies [Mader et al., 2005; Eliassen et al., 2006; Duarte et al., 
2011]. Contrarily to our initial expectations, the bLF-derived peptides did not show higher 
anticancer effects than the full protein. Additionally, we found that it is unlikely that bLF 
gets degraded under the conditions used. Therefore, the observed effects are most likely 
due to the protein itself and not its potential degraded peptides. Considering the specific 
relationship between LF and breast, we used four human breast cancer cell lines with 
different genetic backgrounds and characteristics. We found that LF significantly inhibits 
the growth of all breast cancer cells in a similar magnitude. Hence, this study suggests that 
bLF could have an efficient broad-spectrum anticancer potential, which can be attained in a 
near future in cancer therapy by specifically inducing the re-expression of human LF in 
cancer cells through targeted genetic means. 
The current work allowed us to confirm the anticancer effects of bLF and its variants on 
breast cancer cells through in vitro experiments. Their potential therapeutic effects in vivo 
are not known yet. Also, we confirmed that bLF could efficiently and rapidly enter inside 
cells, although most of it is retained in the extracellular milieu. Therefore, it is crucial to 
conduct a quantitative analysis of the bLF internalization by cells using other 
complementary and more accurate techniques. The comparison between the bLF and 
variants internalization by cells will be another interesting work to be conducted in the 
future. Although some reports demonstrated that holo- and apo-bLF were internalized by 
LF receptors via clathrin-mediated endocytosis [Jiang et al., 2011], the full internalization 
process is still not clear. This knowledge will certainly be very helpful to unravel the 
mechanisms behind the bLF action.  
In conclusion, our data clearly indicated that bLF and some variants could efficiently 
inhibit the proliferation of the four breast cancer cell lines. The comparison of bLF and its 
variants cytotoxicity was also evaluated in this study and we observed that the full proteins 
was more active than some of its peptides. Moreover, we showed that bLF is stable under 
cell culture conditions and is able to internalize cancer cells. The results gathered in this 
study build a solid foundation for the future work on the mechanisms involved in the 
anticancer effects of LF. 
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Chapter 3  
Bovine lactoferrin induces cell cycle 
arrest and inhibits mTOR signaling in 
breast cancer cells 
Abstract 
The anticancer effects of lactoferrin (LF) on multiple cancers have been reported by 
several researchers. We previously found that bovine lactoferrin (bLF) exhibited growth 
inhibitory activity against breast cancer cells without affecting their normal counterparts. 
In the present study we aimed to uncover the mechanisms of action behind the anticancer 
effects of bLF. The bLF growth inhibitory effect was associated with cell cycle arrest and 
not with induction of cell death by apoptosis in all breast cancer cells used (T-47D, 
MDA-MB-231, Hs578T and MCF-7), even at the highest bLF concentration (30 μM) 
studied. Depending on the cell line, the treatment with bLF was found to arrest cells at 
different phases of the cycle. Yet, a marked inhibition of the DNA synthesis (S phase) 
phase was found to be associated with a decrease of the CDC25c levels. Western blot 
assays showed the ability of bLF to increase remarkably phospho-AMPKα levels, as well 
as to downregulate both phospho-mTOR and total mTOR levels, suggesting a novel effect 
of bLF in breast cancer cells that may be associated with its inhibitory effects on cell 
growth. This study disclosed an important step in the understanding of the mechanisms by 
which bLF exerts its anticancer effects that will be of great benefit towards its potential 
application in cancer therapy.  
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3.1 INTRODUCTION 
Natural products have been the main source of anticancer drugs and will continue to be 
an attractive source of new therapeutic candidate compounds in view of the tremendous 
chemical diversity that can be found in millions of species of plants, animals, marine 
organisms and microorganisms [Milner, 2004; Patel et al., 2010]. Indeed, several food 
components have the potential to be effective chemopreventive agents for different human 
diseases [Young et al., 2011]. The successful characterization of these active agents will 
generate immense socioeconomic benefits. However, a large fraction of the active 
molecules present in our diet are still unknown, and the study of their mechanisms of 
action is rather complex [Milner, 2004]. The milk-derived lactoferrin (LF) is an iron 
binding protein predominantly found in mammalian secretions [Adlerova et al., 2008]. 
This protein is well known for its multiple biological functions such as antibacterial, 
antiviral, antitumor, anti-inflammatory and immune regulatory properties [Ushida et al., 
1999; Kuhara et al., 2000; Xiao et al., 2004; Chandra et al., 2006]. Importantly, LF and its 
variants have been proposed for cancer therapy for many years owing to their high 
cytotoxicity and tumor-targeting properties [Tomita et al., 2002; Rodrigues et al., 2009; 
Tsuda et al., 2010]. Despite the existence of a great deal of reports supporting this 
conclusion, little is known about the mechanisms against established tumor cell lines and 
their ability to augment cancer chemotherapy and immunomodulatory mechanisms, by 
which their effects are thought to be mediated [Roy et al., 2002; Sakai et al., 2005; Onishi 
et al., 2008].  
Actually, the LF receptors are widely dispersed on the cell membrane [Fillebeen et al., 
1999; Jiang et al., 2011], and this protein was shown to penetrate through it [Rochard et al., 
1992; Bi et al., 1996]. For example, in Jurkat human lymphoblastic T-cell, LF was found to 
enter cells via the receptor mediated endocytosis [Bi et al., 1996]. Moreover, holo- and 
apo-bLF were shown to internalize cells by an LF receptor via clathrin-mediated 
endocytosis in Caco-2 cells [Fillebeen et al., 1999; Jiang et al., 2011]. However, an 
increased permeability may lead to subtle changes in the membrane’s barrier function, 
ultimately promoting cell death. Other authors refer that LF can increase cytolysis at low 
concentrations while at high concentrations it modulates cytolysis depending on the target 
cell phenotype [Damiens et al., 1998]. This suggests that the LF-receptors aid the 
internalization of LF but this activity could damage the cell membrane. In addition, cell 
cycle arrest is thought to be the main mechanism underlying the LF cytotoxicity against 
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cancers. It generally concerns the upregulation or downregulation of some cell cycle 
associated proteins, such as ERK, AKT, p21, p27, Cdk2, cyclin E, Cdk4, and cyclin D1, 
among others [Lin et al.,2005; Zhou et al., 2008; Xu et al., 2010]. For instance, LF was 
shown to induce the cell cycle arrest of head and neck cancers by decreasing the 
expression of cyclin E and increasing the expression of the Cdk inhibitor p27. According to 
the literature, LF usually induces the cell cycle arrest at the G1 phase [Xiao et al., 2004]. 
Simultaneously, △LF stable expression in cells could also prevent cell cycle progression 
and inhibit cell proliferation [Breton et al., 2004].  
In contrast to the reported cell cycle arrest studies, most apoptosis experiments have 
been conducted with LF-derived peptides, such as LfcinB [Roy et al., 2002; Sakai et al., 
2005; Onishi et al., 2008]. Indeed, there are few reports concerning the LF-induced 
apoptosis [Mader et al., 2005; Furlong et al., 2006; Lee et al., 2009]. These studies suggest 
that LF-induced apoptosis in cancer cells is mainly due to a decrease of the expression of 
the anti-apoptosis protein, Bcl-2 [Lee et al., 2009; Duarte et al., 2011]. Furthermore, PARP 
cleavage and the increase of phospho-p38 and phospho-JNK have also been implicated in 
the LF-induced apoptosis [Schmid et al., 1999]. In fact, it is well-known that JNK and p38 
play a key role in the apoptosis induced by various cellular insults. Moreover, several 
Bcl-2 family proteins, both pro- and anti-apoptotic, are strictly controlled by JNK 
phosphorylation [Cai et al., 2006]. Although these studies demonstrated that LF could 
induce apoptosis in some cancer cell lines, it is still unknown how signals transfer from LF 
to pro-apoptotic molecules. LF is mainly produced and secreted by the breast. Interestingly, 
its downregulation has been associated with an increase of breast cancer incidence 
[Furmanski et al., 1989]. Indeed, the downregulation or silencing of LF expression has 
been found in an extensive series of cancer cells [Siebert＆Huang, 1997; Hoedt et al., 
2010]. It has also been shown that the recovery or overexpression of LF can significantly 
retard cancer cell growth, and also weaken the colony formation [Breton et al., 2004; Zhou 
et al., 2008], thus indicating that LF could play an important role in cancer therapy, 
especially for breast cancers. In a previous work (chapter 2), we also found that LF and its 
variants possess interesting anticancer potential against a wide array of breast cancer cell 
lines by inhibiting cell growth, without significantly affecting normal breast cells. 
The aim of this study was to evaluate the bLF anticancer mechanisms against several 
breast cancer cells. Cell lines used included three p53 mutant cell lines (MDA-MB-231, 
Hs578T and T-47D) and one p53-positive cell line (MCF-7); T-47D and MCF-7 are 
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estrogen-receptor-positive (ER+), while MDA-MB-231 and Hs578T have negative 
estrogen receptors (ER-) [Mercatante et al., 2002; Zhuang et al., 2008]. 
 
3.2 MATERIALS AND METHODS  
3.2.1 Cell lines and lactoferrin 
T-47D and MDA-MB-231 breast cancer cell lines were kindly provided by IPATIMUP 
and Medical School from University of Porto (Portugal), respectively. Hs578T cells were a 
kind gift from Life and Health Sciences Research Institute, University of Minho (Portugal). 
MCF-7 was obtained from the American Type Culture Collection. The cells were cultured 
in L-glutamine-containing DMEM medium (Biochrom AG, Berlin, Germany) 
supplemented with 10% fetal bovine serum (FBS) (Biochrom AG), 100 U/ml 
penicillin/streptomycin (Sigma-Aldrich, Steinheim, Germany) at 37℃ in a humidified 
incubator with a 5% CO2 atmosphere. Bovine lactoferrin was bought from the company of 
DMV (Veghel, The Netherlands). The purity of the protein is about 80% with 3.5% 
moisture, and its iron content is around 120 ppm (0.12‰). In other words, the iron 
saturation of the bLF is about 21% iron-content. 
 
3.2.2 Cell cycle analysis 
Cells (T-47D, MDA-MB-231, Hs578T and MCF-7) were seeded on a 100 mm petri dish 
and cultured for 24 h. Fresh medium with different concentrations of bLF (7.5 μM, 15 μM 
and 30 μM) was added to cells and incubated for 48 h. Afterwards, cells were fixed with 70% 
ice-cold ethanol for 15 min. Next, cells were washed twice with phosphate buffered saline 
(PBS) and then resuspended in 500 μL PBS. A 50 μL volume of RNAse A (200 µg/ml) 
solution was added to each sample and these were further incubated at 37℃ for 15 min. 
Finally, 60 μL of propidium iodide (PI) (0.5 mg/ml) was added to the samples and these 
were incubated for 30 min at room temperature prior to flow cytometry analysis (Coulter 
Epics XL flow cytometer, Beckman Coulter Inc., Miami, FL, USA). For cell cycle analysis, 
at least 30,000 single cells per sample were used, and fitting to the cell cycle phases was 
done using the mathematical Watson Pragmatic model with the FlowJo Analysis Software 
(Tree Star, Inc., Ashland, OR, USA). 
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3.2.3 Assessment of apoptosis by nuclear condensation assay 
Cells (T-47D, MDA-MB-231, Hs578T and MCF-7) at exponential phase were collected 
and seeded in 6-well-plates. Cells were grown for 24 h before bLF treatment at several 
concentrations (7.5 μM, 15 μM and 30 μM). After 72 h, both floating and attached cells 
were collected and fixed with 4% (w/v) paraformaldehyde in PBS for 20 min at room 
temperature. Next, cells were washed and attached into a polylysine-treated slide using a 
Shandon Cytospin 4 (Thermo Scientific, Waltham, MA, USA), and nuclei were stained 
with Hoechst (5 µg/ml) for 10 min in the dark. Fluorescent-dyed cells were observed and 
images were captured using an Olympus IX71 microscope (Hamburg, Germany). More 
than 400 cells per sample were counted using different fields and the apoptosis rate was 
calculated according to the following equation (Equation 3.1): 
 
               Number of cells with nuclear condensation 
 % Apoptosis =  
Total number of cells (stained blue) 
Equation 3.1 
 
 
3.2.4 Assessment of apoptosis by Annexin V / PI assay  
T-47D and MDA-MB-231 cells were treated with 30 μM bLF for 24 h. Subsequently, 
cells were washed with PBS and resuspended in 1X Binding Buffer (0.01 M Hepes - pH 
7.4, 0.14 M NaCl, 2.5 mM CaCl2) at a concentration of 1×10
6
 cells/ml. A 100 μl volume of 
each sample was stained with 5 μl FITC Annexin V (BD Pharmingen, BD, Franklin Lakes, 
NJ, USA) and 10 μl PI (50 µg/ml). Afterwards, the samples were gently mixed in a vortex 
and further incubated at room temperature for 15 min in the dark. Finally, 400 μl of 1X 
Binding Buffer was added to each sample and these were analyzed by flow cytometry.  
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3.2.5 Histone extraction 
Total histone extraction was used to measure the levels of phospho-histone H2A.X as a 
marker of DNA damage. For that, T-47D cells were incubated with 15 μM and 30 μM bLF 
for 1 h, 6 h and 12 h. Incubation of cells with 50 μM etoposide was used as positive control 
for DNA damage. Cells were collected and washed with ice-cold PBS. Next, cells were 
resuspended in Triton Extraction Buffer (TEB: PBS with 0.5% Triton X-100 (v/v), 2 mM 
phenylmethylsulfonyl fluoride, 0.02% (w/v) NaN3) at a cell density of 1×10
7
 cells/ml. The 
cell suspension was left on ice for 10 min with gentle stirring, nuclei was centrifuged at 
6,500 xg for 10 min at 4ºC and washed once with half volume of TEB. Subsequently, the 
nuclei pellet was resuspended in 0.2 N HCl at a density of 4×10
7
 nuclei/ml to perform an 
acid extraction of histones overnight at 4℃ . After centrifugation, the supernatant 
containing histone protein was used for further analysis or otherwise stored at -80℃.  
 
3.2.6 Total protein extraction  
T-47D, MDA-MB-231, Hs578T and MCF-7 cells were grown in 6-well-plates and 
further treated with bLF at several concentrations (7.5 μM, 15 μM and 30 μM) for 16 h and 
48 h. Furthermore, to detect the effects of bLF on the phosphorylation of AKT and ERK in 
a short term, T-47D and MCF-7 cells were treated for 30 min, 1 h, 2 h, 3 h and 6 h without 
refreshing the culture medium. At a definite time, cells were washed twice with PBS and 
lysed in RIPA (Radio-Immunoprecipitation Assay) buffer (50 mM Tris-HCl pH=7.5, 1% 
(v/v) NP-40, 150 mM NaCl, 2 mM EDTA, and added fresh 20 mM Na3VO4, 20 mM NaF, 
1 mM PMSF and protease inhibitory cocktail (Roche)) on ice for 15 min. Subsequently, the 
cell homogenate was centrifuged at 10,000 xg at 4ºC to pellet the cell debris. The 
supernatant was collected and stored at -80℃ for further analysis of different protein 
levels by western blot.  
 
3.2.7 Quantification of protein and Western blot 
The concentration of the protein was determined by the detergent compatible DC Protein 
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assay (Bio-Rad Laboratories, Inc., Hercules, CA, USA) for total protein extracts, while the 
histone protein extracts were quantified using the Bradford reagent from Sigma-Aldrich. 
Bovine serum albumin (BSA) was used as protein standard. For the SDS-PAGE, 20 μg or 
30 μg of protein from each sample was mixed with Laemmli’s buffer [Nirmalan et al., 
2009] and these were held in boiling water for 5 min for protein denaturation. Next, after 
separating proteins in the SDS-PAGE gel, they were electroblotted to a hydrophobic 
polyvinylidene difluoride (PVDF) membrane (GE Healthcare, Bucks, UK), and the 
membranes were blocked in TPBS (PBS with 0.05% (v/v) Tween-20) containing 5% (w/v) 
nonfat dry milk. After washing in TPBS, membranes were incubated overnight at 4ºC with 
a specific primary antibody of interest, followed by washing and incubation with a 
secondary antibody for 1 h at room temperature. Immunoreactive bands were detected 
using the Immobilon solutions (Millipore, Billerica, MA, USA) under a 
chemiluminescence detection system, the Chemi Doc XRS (Bio-Rad Laboratories, Inc.). 
Band area intensity was quantified using the Quantity One software from Bio-Rad. β-actin 
was used as loading control. The antibodies used were the following: 
anti-phospho-AMPKα (thr172), anti-AMPKα, anti-CDC25c, anti-phospho-JNK and 
anti-JNK acquired from Santa Cruz Biotechnology (Santa Cruz, CA, USA); 
anti-phospho-mTOR, anti-mTOR, anti-phospho-AKT, anti-AKT, anti-phospho-ERK, 
anti-ERK, anti-phospho-p38 and anti-p38 bought from Cell Signaling (Danvers, MA, 
USA); anti-β-actin was from Sigma-Aldrich; antibody against phospho-histone H2A.X 
(Ser139, clone JBW301) was from Millipore. 
 
3.3 RESULTS 
3.3.1 Lactoferrin failed to induce apoptosis in breast cancer cells 
Apoptosis-inducing agents are generally considered the most favorable anticancer drugs 
since apoptosis is a process of programmed cell death and does not lead to an undesirable 
inflammatory response. Some previous studies showed that bLF could induce apoptosis in 
cancer cells [Mader et al., 2005; Furlong et al., 2006; Xu et al., 2010]. The cell viability 
results (Chapter 2) indicated that bLF could efficiently inhibit the growth of T-47D, 
MDA-MB-231, Hs578T and MCF-7 cells. Herein, we aimed to evaluate whether inhibition 
of cell growth of those cell lines by bLF could be associated with the induction of cell 
apoptosis. By the nuclear condensation assay, no apoptotic cells could be found for all the 
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studied cell lines after a 72 h period of treatment with bLF at 7.5 μM, 15 μM and 30 μM 
(Figure 3.1A (this figure only shows results for the highest bLF concentration tested)). 
Moreover, we also performed the Annexin V/PI assay since it is a useful tool to assess 
early apoptosis events. These experiments were done with T-47D and MDA-MB-231 cells 
to confirm the nuclear condensation results. Likewise, no apoptotic cells (Annexin V 
positive/PI negative cells) could be observed for both cell lines subjected to a 24 h 
treatment with 30 μM bLF (Figure 3.1B). The results suggest that the previous observed 
bLF effects on the cell growth of the four breast cancer cells is not due to cell death by 
apoptosis but can be due to inhibition of cell proliferation. In fact, by microscopic 
observations (data not shown), cells treated with the highest concentration of bLF (30 μM) 
showed evident inhibition of cell proliferation (lower cell number) without presenting 
increased number of floating cells (dead cells). 
 
 
Figure 3.1 – Effect of bLF in cell death by apoptosis. (A) Apoptotic cells in T-47D, MDA-MB-231, 
Hs578T and MCF-7 cell lines were evaluated using the nuclear condensation assay after 72 h incubation 
with 30 μM bLF. (B) Apoptotic cells in T-47D and MDA-MB-231 cell lines were evaluated by the 
annexin V/ PI assay after 24 h incubation with 30 μM bLF. Results correspond to a representative 
experiment from three independent experiments with similar results. 
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3.3.2 Apoptosis-associated JNK and p38 pathways were not affected by 
bovine lactoferrin 
It is well known that the persistent activation of JNK and p38 stress-induced kinases is a 
key factor for cells to undergo apoptosis [Cai B et al, 2006]. Therefore, their involvement 
on bLF effects in breast cancer cells were evaluated by western blot, measuring their 
phosphorylation levels as an indication of signal activation. As can be seen in Figure 3.2, 
no differences could be found in the expression of phospho-JNK and phospho-p38 between 
bLF-treated groups and control group in the cancer cells. Furthermore, no differences 
could be observed among the different bLF concentrations studied. These results indicate 
that both JNK and p38 signaling pathways are not involved in the anticancer effects of bLF, 
and further confirm that apoptosis is not involved in growth inhibition induced by bLF.  
 
3.3.3 Lactoferrin induced cell cycle arrest in breast cancer cells 
Since apoptosis was not observed, we then tested whether cell growth inhibition induced 
by bLF (Chapter 2) could be due to the retardation of cell division. For that purpose, the   
 
 
Figure 3.2 – Expression of JNK and p38 pathways in breast cancer cells exposed to bLF. T-47D, 
MDA-MB-231 and MCF-7 cells were incubated with different bLF concentrations for 48 h. The protein 
level of JNK and p38 in these cells were evaluated by western blot. The blots are representative of three 
independent experiments with similar results. β-actin was used as loading control. 
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effect of bLF on cell cycle progression was investigated by flow cytometry. After exposure 
to bLF for 48 h, it could be clearly observed a very strong inhibitory effect on the cell cycle 
progression for the MDA-MB-231 and MCF-7 breast cancer cells. Curiously, it was found 
that the bLF-induced cell cycle arrest was cell-type dependent (Figure 3.3). For the 
MDA-MB-231 cell line, bLF induced cell cycle arrest at the G2 phase. The proportion of 
cells at G2 phase increased with increasing bLF concentrations. In MCF-7 cells, a different 
behavior of cell cycle as a result to the bLF treatment was observed. At lower bLF 
concentrations a strong G1 arrest was observed, but a higher concentration (30 μM) was 
also accompanied by a G2 arrest. The cell cycle inhibition in T-47D and Hs578T cell lines 
was much less evident. Using 30 μM of bLF, a G2 arrest was found in T-47D cells, 
whereas a G1 arrest occurs for Hs578T cells. Interestingly, with the exception of T-47D 
cells, in all the other 3 cell lines bLF induced a marked decrease in the number of cells at 
the S phase, indicating that DNA synthesis was being inhibited in the presence of bLF. 
These results show that bLF inhibits cell growth of breast cancer cells by interrupting 
the cell cycle progression, but induces cell cycle arrest at distinct checkpoints depending 
on the cells used. For MCF-7 cell line, it was found that different bLF concentrations lead 
to distinct effects on the cell cycle progression.  
 
3.3.4 DNA damage assay 
DNA damage is one of the main events that lead to cell cycle arrest [Dasika et al., 1999]. 
Since it was shown by us (chapter 2) and others [Bi et al., 1996; Jiang et al., 2011] that 
cells can internalize bLF, it is plausible to think that bLF may arrest the cell cycle by 
inducing DNA damage. A very early step in the cellular response to DNA double-strand 
breaks (DSBs) is the phosphorylation of a histone H2A variant, H2A.X, at the sites of 
DNA damage [Burma et al., 2001]. Therefore, the phosphorylation levels of histone 
H2A.X can be used as a marker of DNA damage. As shown in Figure 3.4, exposure of 
T-47D cells to bLF concentrations of 15 μM and 30 μM did not induce phosphorylaton of 
histone H2A.X, contrarily to the positive control etoposide. Therefore, these results 
demonstrate that the induction of cell cycle arrest by bLF was not due to DNA 
double-strand breaks.  
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Figure 3.3 – Cell cycle progression in breast cancer cells exposed to different bLF concentrations for 48 
h. T-47D, MDA-MB-231, Hs578T and MCF-7 cells were incubated with different concentrations of 
bLF for 48 h, and the cell cycle of cells were analyzed by flow cytometry. These are representative 
results from three independent experiments with similar results.  
 
3.3.5 Lactoferrin did not inhibit ERK and AKT pathways 
ERK and AKT pathways play an important role in cell proliferation and cell cycle 
progression. ERK regulates the phase transitions G1/S and G2/M in cell division, while 
AKT is a key regulator in the G1/S transition [Worster et al., 2012]. In previous reports, 
downregulation of phospho-ERK (p-ERK) and/or phospho-AKT (p-AKT) was associated 
with bLF-induced cell cycle arrest [Damiens et al., 1999; Xu et al., 2010]. In this study, we 
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Figure 3.4 – Effect of bLF in the ability to induce DNA double-strand breaks, as measured by the 
phospho-histone H2A.X levels. This was evaluated in T-47D cells by western blot after incubation with 
bLF at 15 μM and 30 μM for different time points. Etoposide at 50 μM was used as positive control. 
The image is the representative bots of three independent experiments.  
 
also measured the activity of the MAPK/ERK and PI3K/AKT signaling pathways b y
measuring through western blot the phosphorylation levels of ERK and AKT, respectively. 
However, contrarily to previous studies in other cell lines, we did not found any significant 
difference in the levels of p-ERK and p-AKT after 16 h of bLF treatment in both T-47D 
and MDA-MB-231 cells (Figure 3.5). Phospho-AKT and phospho-ERK were not present 
in T-47D and MDA-MB-231 cells, respectively. These results indicate that the molecular 
mechanisms underlying the bLF-induced cell cycle arrest in the breast cancer cells does 
not involve the ERK and AKT pathways. 
 
 
Figure 3.5 – Expression of ERK and AKT pathways in breast cancer cells exposed to different bLF 
concentrations for 16 h, as assessed by western blotting. This experiment was repeated three times with 
similar results. β-actin was used as control. 
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3.3.6 Lactoferrin increased the phosphorylation of ERK and AKT at an 
early stage  
  As shown above, no obvious inhibition of the ERK and AKT pathways could be 
observed due to cells treatment with bLF for 16 h. However, this does not exclude the 
possibility that the bLF could be affecting these pathways in a shorter exposure time. 
Therefore, several assays were conducted at times ranging from 30 min to 6 h, in which 
bLF was added to cells without refreshing the medium to exclude any possible influence 
from fresh FBS (containing mitogenic components) on these signaling pathways. As shown 
in Figure 3.6, bLF at 15 μM greatly increased the phosphorylation of ERK and AKT in a 
short period (30 min) of exposure time, for T-47D (Figure 3.6A) and MCF-7 (Figure 3.6B) 
cells, respectively. Afterwards, a decrease of phosphorylation was observed from 1 h to 6 h. 
However, phospho-AKT in T-47D and phospho-ERK in MCF-7 was not detected in a short 
term. These results indicate that bLF has a mitogenic potential at the early stages, but then 
by an unknown mechanism this protein affects the growth of breast cancer cells by
inducing cell cycle arrest. This mitogenic potential of bLF at an early stage may explain 
why the cell cycle arrest was not very pronounced after 24 h of bLF treatment at the 
different concentrations tested (data not shown). 
 
3.3.7 Lactoferrin decreased the phosphorylation and expression of 
mTOR 
Although the short-term effects of bLF were contradictory with the observed bLF cell 
growth inhibition against the breast cancer cells, this finding led us to focus the research on 
the study of nutrient-related factors that could possibly be involved in the cell cycle arrest. 
Recent studies had demonstrated that the serine-threonine mammalian target of rapamycin 
(mTOR) is an important nutrient/energy sensor. Indeed, mTOR can integrate multiple 
signals and serves as a central regulator in cell survival, metabolism and cell proliferation 
[Tokunaga et al., 2004; Morgensztern＆McLeod, 2005]. Therefore, the levels of 
phospho-mTOR and total mTOR in the breast cancer cells treated with bLF were evaluated 
by western blot. The results showed that 30 μM bLF efficiently inhibit the phosphorylation 
of mTOR after 2 h and 20 h treatment (Figure 3.7A). Furthermore, it was also found that 
bLF not only decreased the phosphorylation of mTOR, but also decreased the total levels   
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Figure 3.6 - Short-term effects of bLF on the phosphorylation of ERK and AKT. Cells were incubated 
with 15 μM bLF for 30 min, 1 h, 2 h, 3 h and 6 h (there were no medium change when bLF was added). 
The protein level of p-ERK and p-AKT in T-47D (A) and MDA-MB-231 (B), respectively, was 
analyzed by western blot. β-actin was used as loading control. This image is representative of three 
independent experiments with similar results. 
 
of mTOR. In addition, the phospho-mTOR and mTOR decreased with increasing 
concentrations of bLF after 16 h incubation, which indicated that the bLF inhibitory effects 
on mTOR signaling acted in a dose-dependent manner (Figure 3.7B). A simultaneous
decrease of mTOR and phospho-mTOR is also observable in other studies with other 
agents such as the mTOR kinase inhibitor rapamycin [Vollenbröker et al., 2009; Johnson 
et al., 2009]. These results show that bLF downregulates the mTOR pathway, which may 
inhibit the phosphorylation of p70S6 kinase (S6K1) and 4E-binding protein 1 (4E-BP1), 
affecting protein translation, autophagy survival pathway and cell cycle progression [Noh 
et al., 2004]. 
 
3.3.8 Lactoferrin increased the phosphorylation of AMPKα 
The AMP-activated serine/threonine protein kinase (AMPK), a sensor of cellular energy 
status, can be activated by low intracellular ATP following some stresses such as nutrient 
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deprivation or hypoxia [Zhuang＆Miskimins, 2008]. Several studies demonstrated that 
mTOR is one of the major downstream signaling pathways regulated by AMPK 
[Shackelford＆Shaw, 2009]. AMPK induces the rapid suppression of mTOR by directly 
phosphorylating TSC2 tumor suppressor and the critical mTORC1 binding subunit raptor 
[Tokunaga et al., 2004]. Therefore, in the current study, the phosphorylation levels of 
AMPKα were evaluated by western blot. As shown in Figure 3.8, bLF induced an increase 
in the levels of phospho-AMPKα in a dose-dependent manner after 48 h of treatment in all 
breast cancer cell lines studied. Therefore, activation of AMPK by bLF may explain the 
inhibition of mTOR signaling leading cancer breast cells to stop growing. To confirm cell 
cycle inhibition, the levels of CDC25c, a crucial player in the G2/M phase transition of the 
cell cycle [Tamura et al., 2000], was also measured and we found that it was clearly 
decreased in bLF-treated cells. Moreover, the bLF inhibitory effects on the cells CDC25c 
expression were found to be in concentration-dependent manner.  
 
 
Figure 3.7 – Evaluation of bLF effect in the expression of phospho-mTOR and mTOR levels in several 
breast cancer cell lines. Cells were incubated with the same concentration of bLF for 2 h and 20 h (A)  
or treated by different concentrations of bLF for 16 h (B). The relative protein levels in the respective 
cells were measured by western blot. The blots are representative of three independent experiments with 
similar results. β-actin was used as loading control. 
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Figure 3.8 – Evaluation of the bLF effect on the expression of AMPKα and CDC25c in breast cancer 
cells. Cells were incubated with different concentrations of bLF for 48 h and the protein level of 
phospho (p) - AMPKα, AMPKα and CDC25c were evaluated by western blot. Shown bots are 
representative of three independent experiments with similar results. β-actin was used as loading 
control. 
 
3.4 DISCUSSION  
Multiple functions have been described for LF including its anticancer effects, which 
regarding breast cancer is corroborated by the association between LF expression and 
cancer risk [Furmanski et al., 1989]. In a previous study we found that bLF is able to be 
internalized by cells and induces growth inhibition of several breast cancer cell lines 
(chapter 2). In the present study, we aim to unravel the mechanisms of action involved in 
the anticancer potential of bLF against breast cancer cell lines with different genetic 
backgrounds. We have found that the anticancer effect of bLF is associated with cell cycle 
arrest and not with induction of cell death by apoptosis. However, many studies reported 
that bLF is able to induce apoptosis in several cancer cell lines [Xu et al., 2010; Furlong et 
al., 2006; Duarte et al., 2011], which indicates that the effects may be dependent on the 
cancer type and/or concentration of bLF used. Yet, the majority of these studies used LF 
extracted from human milk to show its apoptosis-inducing activity [Damiens et al., 1999; 
Lin et al, 2005; Lee et al., 2009], which may also explain the different outcome between 
their results and ours. In our study, the lack of apoptosis in the presence of bLF may also 
be due to the resistance of the cell lines to this type of cell death. As it is known, one of the 
hallmarks of cancer cells is their potential to escape from cell death by apoptosis [Igney ＆ 
Krammer, 2002]. For example, p53 is a well-known pro-apoptotic protein, but mutations in 
the p53 gene that affect its normal functions as tumor suppressor occur in approximately 
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50% of sporadic human tumors [Gasco et al., 2002; Meulmeester＆Jochemsen, 2008]. The 
cell lines T-47D, MDA-MB-231 and Hs578T all possess a somatic mutation in the p53 
gene locus [Mercatante, et al., 2002]. Although p53 is wild type in MCF-7 cells, this cell 
line is also known as resistant to apoptosis, probably due to the lack of expression of the 
apoptotic effector caspase-3 [Jänicke, 2009]. 
In this work, a systematic evaluation of bLF effects on cell cycle was done by flow 
cytometry in multiple breast cancer cells. The results demonstrated the ability of bLF to 
induce cell cycle arrest in T-47D, MDA-MB-231, Hs578T and MCF-7 cells. However, the 
phase of cell cycle in which the cells were arrested differed from cell line to cell line, 
probably due to their different genetic backgrounds. Nevertheless, a decrease in the 
number of cells synthesizing DNA (cells at S phase) and inhibition of CDC25c levels was 
a common feature in the effect of this protein in cell cycle progression, corroborating 
therefore the ability of bLF to inhibit cell proliferation. Other studies also found that LF is 
able to induce cell cycle arrest in cancer cells [Xiao et al., 2004; Damiens et al., 1999; 
Yamada et al., 2008]. For example, human lactoferrin (hLF) induced cell cycle arrest at G1 
to S transition in MDA-MB-231 cells by decreasing Cdk2 and Cdk4 activity and inducing 
the expression of p21 [Damiens et al.,1999]. Likewise in our study, bLF induced cell cycle 
arrest in MDA-MB-231 cells but this occurred at G2/M phase, indicating that the 
anticancer mechanism of action of LF may be dependent on the protein species source. 
Since induction of DNA damage is also correlated with cell cycle arrest [Dasika et al., 
1999], we tested herein whether inhibition of cell growth by bLF would be dependent on 
DNA double strand breaks. However, this hypothesis was discarded since bLF did not 
induce phosphorylation of the histone H2A.X. 
Many signaling pathways, such as MAP kinases and PI3K/AKT, are commonly altered 
in cancer affecting cell proliferation and mechanisms of cell death by apoptosis [Roy et al., 
2010]. Some studies have shown the involvement of AKT in the anticancer effects of LF 
against stomach cancer cells [Xu et al., 2010], whereas JNK was required for the apoptosis 
induced by bLF [Lee et al., 2009]. In our study, bLF did not induce the stress-induced 
kinases JNK and p38, and therefore these results are in accordance with the lack of 
apoptosis. On the other hand, the MAPK/ERK and PI3K/AKT signaling pathways were 
not inhibited by bLF indicating that they were not implicated in the cell cycle arrest 
observed in all breast cancer cells used. However, in the short-term bLF induced both the 
phosphorylation of AKT and ERK, but they return to normal levels after few hours. This 
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effect is associated with a signal for growth and proliferation as it occurs due to mitogenic 
factors present in FBS [Worster et al., 2012]. Although this effect is contrary to the 
inhibition of cell proliferation observed here, bLF may have other cellular effects that 
surpass this earlier event. Interestingly, a previous study also found that hLF had a 
bi-directional action on apoptosis and ERK pathway depending on the dose used in PC12 
cells [Lin et al., 2005]. Herein, a bi-directional action of bLF in cell proliferation events 
seems to depend on time. 
To further advance in the search for the possible mechanisms behind the growth 
inhibition of bLF, the nutrient/energy sensor mTOR kinase that integrates multiple signals 
and known to regulate cell survival (autophagy), metabolism and cell proliferation 
[Tokunaga et al., 2004; Kim et al., 2011], was studied. Interestingly, we observed that bLF 
induced in all breast cell lines a fast downregulation of this signaling pathway, in view of 
both the decrease of total and phosphorylated forms of mTOR. The upstream effector of 
mTOR, AKT [Morgensztern＆McLeod, 2005], probably was not responsible for this effect 
since it was not downregulated by bLF and, on the contrary, it was even induced in the first 
hours of incubation. The energy sensor AMPK is another upstream effector of mTOR 
[Shackelford＆Shaw, 2009], and here a remarkable activation of phospho-AMPK in breast 
cancer cells was observed in the presence of bLF. Therefore, a downregulation of mTOR 
through activation of AMPK may explain the ability of bLF to inhibit cell growth and to 
induce cell cycle arrest. Inhibition of protein synthesis in cells through mTOR is expected 
to markedly retard cell proliferation since many cell cycle-related proteins need to be 
coordinately synthesized and degraded at different phases for cell cycle to progress 
[Tokunaga et al., 2004; Kim et al., 2011]. As far as we know, this is the first report 
showing the effects of bLF in AMPK and mTOR kinases, which may be relevant in the 
fight against breast cancer cells since this signaling pathway is considered an important 
target for cancer treatment [Noh et al., 2004]. However, more studies are needed to 
confirm the involvement of AMPK/mTOR axis in the growth inhibition potential of bLF, 
in particular to explain how a high concentration of the protein bLF in cell culture medium 
induces a starvation-like state in breast cancer cells.  
bLF has been largely produced at an industrial scale and is currently used as a food 
supplement with health benefits [Y.Z. et al., 2008; Manzoni et al., 2009]. bLF, as a 
milk-derived protein, is relative more safe than other anticancer agents, especially when it 
shares 70% sequence homology with human LF [Nozaki A et al., 2003]. Therefore, this 
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protein may have a great potential for application in cancer therapy. However, the in vivo 
evaluation of bLF will be essential if a clinical application is foreseen. Nevertheless, some 
previous reports succeeded to show the LF potential as antitumor agent in vivo using 
animal models [Fischer et al., 2006; Wolf et al., 2007]. 
In summary, this study reported that bLF possesses an interesting anticancer activity 
against breast cancer cells. This activity was found to be associated to cell cycle arrest but 
not to cell death by apoptosis. Some insights on the mechanisms behind the bLF growth 
inhibitory effects in the four breast cancer cells were also provided. The observed effects 
were not associated with modulation of the signaling pathways JNK, p38, MAPK/ERK and 
PI3K/AKT. Interestingly, cell cycle arrest induced by bLF was found to be associated with 
a downregulation of mTOR signaling probably due to AMPK activation. We believe that 
the direct anticancer effects of bLF plus its immunostimulatory effects will lead to a 
pronounced anticancer activity in vivo, and therefore that this protein could be envisaged as 
a powerful agent for cancer therapy in a near future.  
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 Chapter 4 
Bovine lactoferrin selectively induces 
apoptosis of breast cancer cells  
Abstract 
Apoptosis is a mechanism that has been reported to be involved in the lactoferrin (LF) 
anticancer effects. We previously showed that bovine lactoferrin (bLF) at concentrations 
lower than 30 μM inhibits the growth of breast cancer cells by induction of cell cycle arrest 
without notorious effects in cell death by apoptosis. In this study, higher concentrations of 
bLF were used against the same breast cancer cell lines under study (T-47D, 
MDA-MB-231, Hs578T and MCF-7 cells) and the anticancer mechanisms were evaluated. 
The results showed that bLF at concentrations ranging from 12.5 μM to 175 μM for 48 h 
induced growth inhibition in a concentration-dependent manner in all breast cancer cells. 
However, bLF only induced apoptosis in MCF-7 cancer cells. Moreover, the mechanism 
underlying the bLF cytotoxicity against MCF-7 cells also included cell cycle arrest at 
G1/G0 phase. The bLF-induced apoptosis was associated with mitochondria membrane 
depolarization and with a decrease of Bcl-2 levels, which suggests that bLF induced 
apoptosis by the intrinsic apoptotic pathway. Induction of cell cycle arrest was also 
corroborated by a significant decrease in the expression of the cell cycle regulator CDC25c. 
Besides, it was excluded the possibility that the bLF anticancer effects could be due to the 
addition of a high concentration of exogenous protein to the culture media, since the same 
concentration of bovine serum albumin failed to affect the cell cycle in the same magnitude 
as bLF. Furthermore, we also showed that bLF clearly restrained the colony formation by 
MCF-7 cells, although promoted cell migration. This later effect was, however, related to 
the presence of a high concentration of exogenous protein. The results gathered in this 
work indicated that the bovine milk-derived protein LF could be viewed in the near future 
as an efficient agent for cancer chemoprevention. 
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4.1 INTRODUCTION 
Due to the safety concerns on the use of pharmaceuticals, as well as their regulatory 
limitations, dietary agents are becoming attractive alternatives as cancer chemopreventive 
agents [Mignogna et al., 2004; Scott et al., 2009]. Some dietary agents, such as selenium, 
vitamin D and green tea polyphenols have been described as potentially applied in the 
chemoprevention of prostate cancer [Syed et al., 2007]. Lactoferrin (LF), a milk-derived 
glycoprotein, is widely distributed in several secretion fluids of mammalian cells but it is 
extremely abundant in milk. This protein has been assigned with multiple biological 
functions, including antibacterial, antiviral, antifungal and immune regulatory activities 
[Adlerova et al., 2008]. More interestingly, it has been found that LF downregulation in 
breast cells could greatly increase the incidence of breast cancers [Furmanski et al., 1989]. 
On the other hand, the exogenous application of LF and its variants were reported to 
efficiently inhibit the cancer growth both in vitro and in vivo [Xu et al., 2010; Yamada et 
al., 2008; Damiens et al., 1999].  
Despite its great potential, the mechanisms underlying the LF and its variants 
cytotoxicity against cancer cells are still fairly unknown. The genetically-induced 
overexpression of human lactoferrin (hLF) in MCF-7 cells was reported to promote 
cellular apoptotic activities [Liao et al., 2010]. Also, recombination adenovirus-mediated 
hLF cDNA led to cell cycle arrest and stimulated apoptosis in MCF-7 cells associated with 
a decrease of Bcl-2 [Wang et al., 2012]. Furthermore, the restoration of delta-lactoferrin 
(ΔLF) in HEK 293 cells resulted in cell cycle arrest and growth retardation [Breton et al., 
2004]. Importantly, exogenous hLF could efficiently inhibit the growth of cancer cells and 
induce cell cycle arrest at G1 phase [Damiens et al., 1999; Yamada et al., 2008; Zhou et al., 
2008]. This effect occurred through a p53-independent pathway, and the key G1 regulatory 
proteins played an important role in the process [Damiens et al., 1999; Yamada et al., 
2008]. Additionally, bovine lactoferrin (bLF) was found to induce apoptosis of SGC-7901 
human stomach cancer cells by inhibiting the Akt activation and regulating its downstream 
signals [Xu et al., 2010]. However, hLF-induced apoptosis in PC12 cells (rat 
pheochromocytoma cells) was observed to be associated to a decrease in the expression of 
the phosphorylated extracellular-signal-regulated kinase 1/2 (ERK1/2) and Bcl-2 [Lin et al., 
2005]. In addition, hLF was reported to induce apoptosis of Jurkat T cells via the 
regulation of c-Jun N-terminal kinase (JNK) activity [Lee et al., 2009]. Furthermore, the 
main bLF-derived peptide, LfcinB, also showed similar effects as its parent protein. 
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Nevertheless, LfcinB inhibited the proliferation of cancer cells mainly by activating 
apoptosis-inducing pathways [Roy et al., 2002; Sakai et al., 2005; Furlong et al., 2006; 
Onishi et al., 2008]. JNK/SAPK (stress-activated protein kinase) activation, 
downregulation of Bcl-2, mitochondria swelling and release of cytochrome c were believed 
to be the mechanisms underlying the LfcinB cytotoxicity against cancer cells [Mader et al., 
2005; Sakai et al., 2005]. All these reports suggest that the mechanisms behind LF and 
LfcinB activities against cancer cells are greatly dependent on the cell type. Additionally, 
the potential of LF for application in cancer therapy was further confirmed in vivo. LF 
exerts the in vivo anticancer ability mainly through activating both the innate and adaptive 
immune responses and stimulating the proliferation and differentiation of T helper cells 
(Th) into type 1 helper cell (Th1) or type 2 helper cell (Th2) phenotypes, which release 
tumor-killing cytokines (Tumor necrosis factors (TNF), interferon-γ (IFN-γ), caspase-1 and 
interleukin-18 (IL-18)) in the intestine and tumor [Fischer et al., 2006; de la Rosa et al., 
2008].  
Therefore, considering the correlation between LF and breast cancer, and the fact that 
exogenous LF has been reported to efficiently inhibit cancer growth both in vitro and in 
vivo, we have been studying recently the anticancer effects of bLF in breast cancer cells 
[Duarte et al., 2011]. We showed previously the bLF potential against breast cancer cells 
without affecting the normal counterparts (chapter 2). At concentrations below 30 μM, 
growth inhibitory effects of bLF was shown to be mainly due to cell cycle arrest associated 
with effects at the AMPK-mTOR axis (chapter 3). In the present work, we aimed to 
investigate the bLF cytotoxicity against breast cancer cells at higher concentrations and to 
propose the possible mechanisms involved in its anticancer effect. Evidences provided by 
the in vitro experiments will be of great value towards a future clinical use of bLF in 
cancer therapy.     
 
4.2 MATERIAL AND METHODS 
4.2.1 Cell lines and lactoferrin 
T-47D and MDA-MB-231 breast cancer cell lines were a kind gift from IPATIMUP and 
Medical School from University of Porto (Portugal), respectively. Hs578T cells were 
donated by Life and Health Sciences Research Institute, University of Minho (Portugal). 
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MCF-7 was bought from the American Type Culture Collection. The cells were cultured at 
37℃ in a humidified incubator with a 5% CO2 atmosphere in L-glutamine-containing 
DMEM medium (Biochrom AG, Berlin, Germany) supplemented with 10% fetal bovine 
serum (FBS) (Biochrom AG) and 100 U/ml penicillin/streptomycin (Sigma-Aldrich, 
Steinheim, Germany). Bovine lactoferrin was purchased from the company of DMV 
(Veghel, The Netherlands). The purity of the protein is about 80% with 3.5% moisture and 
21% iron-saturated according to the manufacture. 
 
4.2.2 Cell proliferation assay 
The trypan blue staining was used to estimate cell growth and cell death induced by the 
treatment with bLF. For that, breast cancer cells (MCF-7, T-47D, MDA-MB-231 and 
Hs578T) were seeded in 24-well plates overnight. Afterwards, bLF at several 
concentrations (12.5 μM, 50 μM, 125 μM and 175 μM) was added to each well. After a 48 
h treatment period, both floating and attached cells were collected and resuspended in 
medium to adjust to an adequate cell concentration. A 50 μl volume of suspended cells 
were mixed with 50 μl of trypan blue 0.04% (w/v) (Sigma-Aldrich) and were incubated for 
5 min before counting viable and non-viable cells using a haemocytometer under a light 
microscope. Cells that exclude trypan blue (viable cells) were used to estimate cell growth, 
where control condition was set as 100%. Cell viability was expressed in percentage and 
calculated according to the following equation: Number of viable cells/total number of 
cells ×100.  
 
4.2.3 Nuclear condensation assay 
The ability of bLF to induce cell death by apoptosis was estimated by the nuclear 
condensation assay. In brief, cells at exponential phase were collected and seeded in 6-well 
plates. After 24 h of incubation, cells were treated for 72 h with bLF at the concentrations 
of 12.5 μM, 50 μM, 125 μM and 175 μM. Then, both floating and attached cells were 
collected and washed with phosphate buffered saline (PBS). Next, cells were immersed in 
4% (w/v) paraformaldehyde for 20 min at room temperature. Afterwards, cells were 
washed once again with PBS and they were fixed to a polylysine-treated slide using a 
Shandon Cytospin 4 (Thermo Scientific, Waltham, MA, USA). Nuclei were stained with 
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Hoechst (5 µg/ml) fluorescent dye for 10 min in the dark. Fluorescent cells were observed 
and photographed using a fluorescent microscope (Olympus IX71, Hamburg, Germany). 
Five different fields from each sample were counted, in order to reach at least 400 cells. 
The apoptosis rate was calculated as the number of cells presenting nuclear condensation 
divided by the total number of cells (stained in blue). 
 
4.2.4 Annexin V/Propidium iodide (PI) staining 
Annexin V/PI staining was also used to estimate cell death by apoptosis. For that, 
MCF-7 cells were seeded in 6-well plates for 24 h. Subsequently, cells were treated with 
12.5 μM, 50 μM, 125 μM and 175 μM bLF. After 48 h of bLF treatment, the cells were 
washed twice with ice-cold PBS and resuspended in 1× Binding Buffer (0.01 M Hepes - 
pH 7.4, 0.14 M NaCl, 2.5 mM CaCl2) to get a final cell concentration of 1×10
6 
cells/ml. A 
100 μl volume of each sample was then stained with 5 μl FITC Annexin V (BD 
Pharmingen, BD, Franklin Lakes, NJ, USA) and 10 μl PI (50 µg/ml). The samples were 
gently vortexed and incubated at room temperature for 15 min in the dark. In the end, 400 
μl of 1× Binding Buffer was added to each sample, which were then analysed by flow 
cytometry using a Coulter Epics XL flow cytometer (Beckman Coulter Inc., Miami, FL, 
USA).  
 
4.2.5 Cell cycle analysis 
MCF-7 cells were seeded on 100 mm petri dish and cultured for 24 h. Fresh medium 
with bLF at the concentrations of 12.5 μM, 50 μM, 125 μM and 175 μM was added to cells 
and incubated for 24 h. In the end, cells were collected and washed with PBS. Further, 
cells were fixed with 70% (v/v) ice-cold ethanol for 15 min on ice. After that, cells were 
washed twice and resuspended in 500 μL PBS. 50 μL RNAse A (200 μg/ml ) was added to 
each sample and incubated at 37℃ for 15 min. At last, 60 μL PI (0.5 mg/ml) was added to 
samples and incubated for 30 min before analysing on a flow cytometer (Beckman Coulter 
Inc.). For cell cycle analysis, at least 30,000 single cells per sample were used and fitted to 
the cell cycle phases using the mathematical Watson Pragmatic model with the FlowJo 
Analysis Software (Tree Star, Inc., Ashland, OR, USA). 
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4.2.6 Mitochondrial membrane potential assay 
MCF-7 cells were incubated with different concentrations of bLF (12.5 μM, 50 μM, 125 
μM and 175 μM) for 2 h, 24 h and 48 h. A positive control was included, containing 
carbonyl cyanide 3-chlorophenylhydrazone (CCCP, Sigma-Aldrich) at a 50 μM and 
incubated for 30 min at 37℃ before cell collection. Subsequently, cells were resuspended 
in 1 ml of warm-PBS, and 10 µl of 200 μM JC-1 (Molecular Probes, Life Technologies, 
Eugene, OR, USA) was added to each sample and incubated for 15 min under cell culture 
conditions. At last, the samples were analysed by flow cytometry (Beckman Coulter Inc.).  
 
4.2.7 Western blot assay 
MCF-7 cells were seeded in 6-well pates 24 h before incubating cells with bLF at the 
concentrations of 12.5 μM, 50 μM, 125 μM and 175 μM for 48 h. After cell washing with 
PBS, total protein was extracted using RIPA (Radio-Immunoprecipitation Assay) buffer 
(50 mM Tris-HCl – pH 7.5, 1% (v/v) NP-40, 150 mM NaCl, 2 mM EDTA, 20 mM 
Na3VO4, 20 mM NaF, 1 mM PMSF, 1× protease inhibitory cocktail). Protein content in 
each sample was determined by the detergent compatible DC protein assay (Bio-Rad 
Laboratories, Inc., Hercules, CA, USA) using BSA as standard. 20 μg or 30 μg protein 
from the samples were loaded into 10% SDS-PAGE and transferred into PVDF membranes 
(GE Healthcare, Bucks, UK). After membrane blocking with TPBS (PBS with 0.05% (v/v) 
Tween-20) containing 5% (w/v) nonfat dry milk, the levels of chosen proteins were 
detected using specific primary antibodies incubated overnight with membranes followed 
by incubation with associated secondary antibodies. Immunoreactive bands were detected 
using the Immobilon solutions (Millipore, Billerica, MA, USA) under a 
chemiluminescence detection system, the ChemiDoc XRS (Bio-Rad Laboratories, Inc.). 
Band area intensity was quantified using the Quantity One software from Bio-Rad. β-actin 
was used as loading control. The antibodies anti-CDC25c, anti-Bcl-2 and anti-p53 were 
acquired from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 
 
4.2.8 Colony formation assay  
MCF-7 cells were trypsinized and pipetted repeatedly to disperse them until single cells 
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account for 95% of the total number of cells. Next, the cells were counted and then seeded 
in 6-well-plates to a concentration of 1×10
3
 cells per well and incubated for 24 h. 
Subsequently, the cells were treated with bLF at several concentrations (12.5 μM, 50 μM, 
125 μM and 175 μM), while DMEM without FBS was used as a positive control. After 24 
h incubation with bLF, the media in all wells was replaced with fresh media (DMEM with 
10% FBS). After 7 to 10 days, the cells were fixed with 70% methanol for 15 min and were 
dried in air. Giemsa was used to stain cells for 10 min and was subsequently washed 
carefully with water. Colonies containing at least 50 cells were counted. Colony formation 
was calculated as the ratio between the number of colonies in the experimental samples 
and the number of colonies in the control sample.  
4.2.9 Migration assay  
The bottom of 6-well-plates was marked with 5-10 straight lines with 0.2 cm interval 
among the lines. Then, 5×10
5
 MCF-7 cells/well were seeded in 6-well plates for growing 
until cell confluence reached over 85%. Then, a scratch wound across each well of the 
6-well plates was made using a pipette tip. Next, cells were washed twice with PBS and 
FBS-free DMEM containing 175 μM bLF or BSA was added. Cells were photographed at 
the exact same point (marked with straight line) in the 6-well plates after 0 h, 6 h, 12 h and 
24 h. The cell migration ratio was calculated by comparing the wound area at 6 h, 12 h and 
24 h to the wound area at 0 h in each group. 
4.2.10 Statistical analysis 
Statistical significance of the experimental results was determined by the Student’s t test. 
For p-values below 0.05 the differences between experimental groups were considered 
significant. 
4.3 RESULTS AND DISCUSSION  
4.3.1 Lactoferrin possess growth inhibitory effects against breast cancer 
cells 
In a previous study, bLF at relatively low concentrations presented interesting growth 
inhibitory effects against a panel of breast cancer cells, as shown by the MTS assay 
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(Chapter 2, Figure 2.1). This effect was associated with cell cycle arrest but not with cell 
death (Chapter 3). In the present study, we have studied higher concentrations of bLF in 
order to test whether the protein is able to induce apoptosis in breast cancer cells. For that 
purpose, the trypan blue staining method was firstly used since it provides information on 
growth inhibitory activities and total cell death. Considering the number of viable cells in 
each well, as it is observed in Figure 4.1, bLF significantly inhibited the growth of breast 
cancer cells after 48 h of treatment in a concentration-dependent manner. The magnitude of 
growth inhibition was identical in all cell lines, which indicates that the effect is not cell 
type specific. When comparing these results with the ones obtained in Chapter 2 at 48 h, it 
was found, as expected, that the degree of inhibition of cells’ growth was remarkably 
increased when using higher bLF concentrations, reaching about 70% to 80% inhibition at 
175 μM (Figure 4.1). In the case of the Hs578T cell line, as compared with non-treated 
cells, cell death increased about 30% due to exposure to 175 μM of bLF. However, few 
dead cells were observed in the other cell lines (data not shown). These results suggest that 
the inhibitory effect of bLF on the breast cancer cells is mostly associated with the 
inhibition of cell proliferation.  
 
4.3.2 Lactoferrin selectively induces apoptosis in MCF-7 cells 
Considering that some cell death was present in the Hs578T cells, we then performed a 
nuclear condensation assay to estimate the potential induction of apoptosis. However, at 48 
h, no evident nuclear condensation was present in all cell lines used (data not shown), 
which corroborate the lack of massive cell death shown above. Since we previously have 
shown that bLF presents some mitogenic effects in the first hours of incubation (Chapter 3), 
we hypothesise that the cell death by apoptosis could be a more delayed event. Therefore, 
induction of apoptosis was evaluated then 72 h after incubation of cells with bLF. The 
results demonstrated that bLF failed to induce apoptosis in all breast cancer cell lines under 
study (data not shown), except for the MCF-7 cells (Figure 4.2). Cells presenting nuclear 
condensation are shown with arrows in Figure 4.2.A. Nuclear condensation was found to 
increase in a dose-dependent way in MCF-7 cells, reaching a ratio of about 35% after 72 h 
of treatment with 175 μM bLF (Figure 4.2.B). This assay indicated that bLF could 
selectively induce apoptosis in MCF-7 cells among the tested breast cancer cells, probably 
due to their different genetic backgrounds. For example, the p53 gene plays an important 
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Figure 4.1 - Effect of bLF on breast cancer cells’ growth. MCF-7, T-47D, MDA-MB-231 and Hs578T 
cells were incubated with bLF at several concentrations for 48 h and cell growth evaluated by cell 
counting of viable cells (not stained with trypan blue). Values are mean  SD of three independent 
experiments. * P < 0.05 and ** P < 0.01 when compared with the control. 
 
role in cell apoptosis [Meulmeester＆Jochemsen, 2008]. Whereas T-47D, MDA-MB-231 
and Hs578T cells harbour a mutated p53 gene, MCF-7 cells possess a wild-type p53 [Xu et 
al., 2007; Jänicke, 2009]. Therefore, the resistance of T-47D, MDA-MB-231 and Hs578T 
cells to undergo apoptosis in the presence of bLF may be due to the lack of the normal 
functions of p53. However, the role of p53 in the induction of apoptosis by bLF needs to be 
confirmed in further experiments. In fact, some studies previously reported the ability of 
LF to induce apoptosis in cancer cells [Lin et al., 2005; Xu et al., 2010; Duarte et al., 2011; 
Wang et al., 2011]. Herein we show that this effect may depend on the genetic background 
of the cell line used, such as the presence of a functional p53 protein. 
To confirm the induction of apoptosis by bLF in the MCF-7 cells, the annexin V/PI 
assay was performed after 40 h of incubation, since the translocation of phosphatidylserine 
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for the outer leaflet of plasma membrane is an apoptotic event that occurs earlier than the 
DNA fragmentation [Elmore, 2007]. The results showed that the amount of non-apoptotic 
cells (Q4 region: annexin V negative/PI negative) decreased in a concentration-dependent 
manner compared to the non-treated group (Figure 4.2.C). In contrast, the number of cells 
in the early stage (Q3 region: annexin V positive/PI negative) and later stage of apoptosis 
(Q2 region: annexin V positive/PI positive) was considerably increased by bLF in a 
concentration-dependent manner (Figure 4.2.C). Although the percentage of apoptotic 
cells in bLF-treated groups estimated by the Annexin V/PI assay was less than that by the 
nuclear condensation assay, this assay confirmed the ability of bLF to induces apoptosis in 
MCF-7 cells. 
  
4.3.3 Lactoferrin inhibits cell cycle progression in MCF-7 cells 
In a previous work, we have shown that induction of cell cycle arrest in the four breast 
cancer cell lines was the major mechanism of cell growth inhibition by bLF at 
concentrations below 30 μM (Chapter 3). Considering that apoptotic cell death was only 
observed in MCF-7 cells, in this work we tested only for this cell line the effects of bLF at 
higher concentrations in the cell cycle progression. As shown in Figure 4.3A, bLF clearly 
induced cell cycle arrest of MCF-7 cells at the G1 phase after 24 h of treatment, and this 
effect increased in a dose-dependent manner. This was accompanied with a remarkable 
decrease in the percentage of cells at the S phase (cells synthesising DNA), therefore 
corroborating the previous results (Chapter 3). These findings are also consistent with 
reports on the LF action against other cancer cell lines [Damiens et al., 1999; Yamada et al., 
2008; Zhou et al., 2008]. Specifically regarding to MCF-7 cells, previous studies 
demonstrated that re-expression of LF or ΔLF using several delivery vectors induced cell 
cycle arrest [Liao et al., 2010; Wang et al., 2012]. In the current work, we showed that 
exogenous bLF presented a similar effect by inhibiting cell proliferation. 
Since the concentration of bLF being used is relatively high (175 μM), reaching a 
quantity of 14 g/L in the culture media, we questioned whether the observed effects could 
be due to this considerable amount of exogenous protein added, which would disturb the 
cellular microenvironment and prevent cell division. Therefore, a parallel assay using bLF 
and bovine serum albumin (BSA) at similar quantities (14 g/L) on the MCF-7 cell cycle 
progression was conducted. As shown in Figure 4.3B, BSA also induced cell cycle arrest  
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Figure 4.2 - Effect of bLF in the induction of cell death by apoptosis in MCF-7 cells. Cells were treated 
with different concentrations of bLF for 40 h or 72 h and apoptosis estimated by the Annexin V/PI and 
the nuclear condensation assays, respectively. (A) Representative images of the nuclear condensation 
assay where apoptotic cells are shown with arrows: white arrows correspond to examples of early 
apoptotic cells (condensed DNA); red arrows correspond to examples of late apoptotic cells (condensed 
and fragmented DNA). Images are provided with a magnification of 400×. (B) Apoptosis rate induced 
by bLF as mean  SD of three independent experiments, as estimated by the nuclear condensation assay. 
* P < 0.05 and ** P < 0.01 when compared with the control. (C) Apoptosis assay by Annexin V/PI 
representative of two independent assays.  
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of MCF-7 cells at the G1 phase. However, this effect was found to be much lower when 
compared to bLF. Moreover, cells incubated with bLF presented a distinct morphology, 
while the morphology of the BSA treated group was very similar to the control one 
(Figure 4.3B). The results gathered in this work suggest that bLF could significantly 
inhibit the MCF-7 cell growth through cell cycle arrest due to a specific biological 
function. 
 
4.3.4 Lactoferrin decreases mitochondrial membrane potential 
Mitochondrial depolarization is considered as an early event in apoptosis that is usually 
associated to the intrinsic apoptosis pathway [Ly et al., 2003]. In this study, we used the 
JC-1 probe to assess the modification of the mitochondrial membrane potential in cells 
after treatment with bLF for 2 h, 24 h and 48 h. After 2 h of bLF treatment at several 
concentrations (12.5 μM, 50 μM, 125 μM and 175 μM), it could be observed a significant 
decrease of the red to green ratio, which represents the decrease of the mitochondrial 
membrane potential. Furthermore, the depolarization effects of bLF on mitochondria
increased in a dose-dependent way (Figure 4.4A). The mitochondrial depolarization 
occurred in all bLF-treated groups after 24 h incubation, although not in a dose-dependent 
manner. Contrarily, after 48 h of bLF treatment, mitochondria depolarization was found to 
be more pronounced and to be dependent on the bLF concentration (Figure 4.4A). From 
the cell distribution in the dot plot graph, it was observed that treatment of MCF-7 cells 
with 175 μM bLF for 48 h led to a significant shift of the number of cells with red to green 
fluorescence, as compared with the non-treated cells (0 μM bLF) (Figure 4.4B). In fact, 
the percentage of cells with depolarized mitochondria after 48 h of bLF treatment (30%) is 
similar to the apoptosis rate observed at 72 h (35%). When cells were observed under a 
fluorescent microscope it was confirmed that bLF induced the depolarization of 
mitochondria in a significant part of the cell population, in contrast to the positive control 
CCCP that basically depolarized the mitochondria of all cells (Figure 4.4B).  
The mitochondrial intrinsic pathway has been reported as the main mechanism of 
LfcinB-induced apoptosis [Sakai et al., 2005; Eliassen et al., 2006]. Our results 
demonstrated that mitochondrial depolarization was also an event associated with the 
bLF-induced apoptosis. Depolarization of the mitochondria membranes was kept during 
the time period ranging from 2 h to 48 h, and no reversible change could be observed. The  
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Figure 4.3 - Effect of bLF in the cell cycle progression of MCF-7 cells. (A) Cells were incubated with 
bLF at several concentrations for 24 h and cell cycle was analyzed by flow cytometry. Results 
correspond to a representative experiment from three independent experiments. (B) Comparison 
between the effect of bLF and BSA at the same concentration on the cell cycle progression of MCF-7 
cells after 24 h of treatment. The top image is representative of cell morphology for each condition 
(magnification of the images: 40×). 
changes in the membrane potential presumably stand for the opening of the mitochondrial 
permeability transition pore, which allows the release of cytochrome c from the 
mitochondria. This is a key event in the initiation of apoptosis [Gottlieb et al., 2003]. 
Therefore, these findings suggest that depolarization of membrane potential is a crucial 
factor in the bLF-induced apoptosis of MCF-7 cells.  
 
4.3.5 Downregulation of Bcl-2 is involved in the lactoferrin-induced 
apoptosis 
Considering that mitochondria membrane depolarization was associated with the 
apoptosis induced by bLF in MCF-7 cells, the expression of Bcl-2 was also studied by 
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western blot. As shown in Figure 4.5, bLF significantly decreased in a 
concentration-dependent manner the expression of anti-apoptotic protein Bcl-2. This is 
totally consistent with the former reports that downregulation of Bcl-2 is associated with 
the LF- and LfcinB-induced apoptosis [Lin et al., 2005; Mader et al., 2005; Xu et al., 2010; 
Wang et al., 2012]. This decrease of Bcl-2 is considered an important event to the opening 
 
 
Figure 4.4 - Effect of bLF on the mitochondrial membrane potential. (A) MCF-7 cells were incubated 
with bLF at several concentrations for 2 h, 24 h and 48 h and mitochondrial membrane potential was 
analyzed by flow cytometer after labeling cells with JC-1 fluorescent probe. The red/green ratio was 
calculated from the respective median fluorescent value, where a decrease of this value in comparison to 
the control is indicative of mitochondrial membrane depolarization. Values correspond to the mean  
SD of three independent experiments. * P < 0.05, ** P < 0.01 and *** P < 0.01 when compared with 
the control. (B) The top image is representative of cells labeled with JC-1 probe, where red cells contain 
polarized mitochondria and green cells contain depolarized mitochondria (magnification of the images: 
400×). The bottom image corresponds to JC-1-labeled MCF-7 cells after 48 h of treatment with 
positive control (CCCP 50 μM) or 175 μM bLF analyzed by flow cytometry. The graphs exhibit the 
percentages of cells with depolarized mitochondria (green positive/red negative).  
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of the mitochondrial permeability transition (MPT) pore and loss of the mitochondrial 
membrane potential, for the release of cytochrome c and other pro-apoptotic proteins 
characteristic of the intrinsic apoptosis pathway [Gottlieb et al., 2003]. It is known that the 
tumour suppressor gene p53 has a critical role in the regulation of Bcl-2 and other proteins 
of the Bcl-2 family [Meulmeester＆Jochemsen, 2008]. As we previously discussed, the 
p53 has probably a key role in the selective apoptosis induction in MCF-7 cells as 
compared with the other breast cancer cells used. However, by western blot analysis we 
did not observed significant changes in the total levels of p53 in the bLF-treated groups 
after 48 h of treatment (Figure 4.5). This does not exclude, however, that p53 may have an 
important function in the bLF-induction of apoptosis in MCF-7 cells, for example through 
its phosphorylation. A previous study with hLF showed, however, that induction of 
apoptosis in cancer cells occurred through a p53-independent mechanism [Damiens et al., 
1999]. 
Related with inhibition of cell proliferation, the levels of CDC25c were measured by 
western blot and shown to clearly decrease after bLF treatment for 48 h (Figure 4.5). 
Although it is not a key regulator in the G1/S transition of cell cycle, the downregulation of 
CDC25c suggests that bLF induced cell cycle arrest through the regulation of key factors 
in the cell cycle progression. This would not be dependent on DNA damage, as we 
previously observed (Chapter 3). 
 
 
Figure 4.5 - Levels of Bcl-2, p53 and CDC25c in MCF-7 cells after treatment with bLF at several 
concentrations for 48 h, as measured by western blotting. The blots are representative of three 
independent experiments with similar results. -Actin was used as loading control. 
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4.3.6 Lactoferrin significantly inhibits the colony formation  
Considering that bLF inhibited cell growth of MCF-7 cells due to both cell cycle arrest 
and induction of apoptosis, we then performed a functional assay to determine the 
effectiveness of the bLF anticancer effect. Therefore, an anchorage-dependent colony 
formation assay was performed, which essentially tests the ability of a single cell to grow 
into a colony by undergoing cell division. Compared with the control (0 μM bLF), the 
bLF-treated cells exhibited a much lower cloning efficiency (Figure 4.6A). The number of 
colonies in the condition treated with 175 µM bLF could only reach 2.6% of the control 
(***P<0.001; Figure 4.6B). Additionally, DMEM media without FBS used as a positive 
control also inhibited the colony formation (Figure 4.6A＆B). These findings are in 
accordance with other reported studies; for example, hLF was previously shown to 
significantly inhibit the colony formation of nasopharyngeal carcinoma cells [Zhang et al., 
2011]. The results gathered in the current work demonstrated that bLF could efficiently 
inhibit the colony formation of MCF-7 cells, thus suggesting that bLF could have a 
potential antitumor effect in vivo. 
 
 
Figure 4.6 - Effect of bLF on the MCF-7 cells ability for anchorage-dependent colony formation. (A) 
Cells were seeded at low density and incubated with several concentrations of bLF and FBS-free 
medium (DMEM) for 24 h. Then, cells were left for 1 week to grow in complete medium to form 
colonies from single cells. Colonies were fixed, stained and images were captured. (B) Quantification of 
colony formation as mean  SD of three independent experiments. ** P < 0.01 and *** P < 0.001, when 
compared with the control (0 μM bLF).  
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4.3.7 Induction of cell migration by bovine lactoferrin in MCF-7 cells is 
not specific for this protein 
Metastasis is the primary cause of mortality in most cancer patients. The repression of 
the metastatic process has been used as an important strategy in cancer therapy. Cell 
migration and invasion are the two key factors involved in the metastasis formation 
[Kramer et al., 2013]. LF was previously described as a promoting factor for the migration 
of MCF-7 cells [Ha et al., 2011]. Herein, we also tested the effect of bLF in cell migration 
and we indeed observed that this protein promotes the migration of MCF-7 cells at 175 μM 
[Figure 4.7]. To test if this effect was only due to the presence of a higher concentration of 
protein in the extracellular milieu, we also compared the results with a condition with the 
same concentration of BSA. As shown in Figure 4.7, cell migration was also greatly 
increased when cells were treated with BSA. Actually, BSA appeared to be more efficient 
in promoting cell migration than the bLF after 6 h of treatment. However, no significant 
differences were found between BSA- and bLF-treated groups after 12 h and 24 h of 
incubation. This result showed that the ability of bLF to induce cell migration is an 
unspecific property and it may result from a positive change of cell microenvironment due 
to the presence of a high concentration of exogenous protein. 
 
4.4 CONCLUSIONS 
In this chapter, bLF at high concentrations (up to 175 μM) was found to selectively 
induce apoptosis in MCF-7 cells among the four breast cancer cells under study. At low 
concentrations, no obvious bLF effect on apoptosis could be found (Chapter 3). This 
suggests that a certain amount of bLF is essential to stimulate the apoptotic event in 
MCF-7 cells. Moreover, apoptosis was found to be a delayed event that could only be 
observed at 48 h with mitochondria depolarization and at 72 h with DNA condensation and 
fragmentation. Furthermore, bLF significantly decreased the anti-apoptotic Bcl-2 protein, 
and in addition to the mitochondrial depolarization, it indicates that is the intrinsic pathway 
that may be involved in the apoptosis induction by this milk protein. The bLF inhibitory 
effect on the MCF-7 cells growth was shown to be associated with the cell cycle arrest at 
the G1 phase. Finally, the bLF anticancer potential against breast cancer cells was 
confirmed by its pronounced ability to inhibit the colony formation. Moreover, bLF 
promoted the migration of MCF-7 cells, but was shown to be an unspecific effect to this  
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protein, and probably not relevant in the in vivo context in view of the high concentration 
of proteins in the biological fluids. 
Interestingly, since the mechanism by which bLF exerts its effect against MCF-7 cells 
was found to be similar to the one reported for hLF [Damiens et al., 1999; Lin et al., 2005; 
Yamada et al., 2008], bLF could be considered as a suitable substitute for hLF with the 
advantage that it can be produced in great amounts from bovine milk. On the other hand, 
the oral administration of bLF has been suggested as a good choice for chemoprevention 
strategies [Kuhara et al., 2000; Tanaka et al, 2000; Norrby et al., 2001]. Therefore, bLF 
could be developed into an efficient nutraceutical to cure or prevent cancer. Our findings 
provide further evidences that bLF could be considered for cancer therapy.  
  
 
Figure 4.7 – Effect of bLF on the migration of MCF-7 cells. Cells were incubated with the same 
concentration of bLF and BSA for 6 h, 12 h and 24 h. (A) Representative images of cell migration into 
the wounded area after 24 h of incubation (Magnification: 40×) (B) Relative wound closure as measured 
by Image J software. Results correspond to the mean  SD of three independent experiments. * P < 0.01 
and ** P < 0.01 when compared with the control or among each other.  
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5.1 CONCLUSIONS 
 Four breast cancer cell lines (T-47D, MDA-MB-231, Hs578T and MCF-7) with 
different characteristics were used to evaluate the potential anticancer effects of bovine 
lactoferrin (bLF) and its derivatives. Similar anticancer effects could be found for the bLF 
extracted from milk and its variants as compared to the ones reported for human lactoferrin 
(hLF). The MTS results showed that bLF at the concentrations of 1.875 μM, 3.75 μM, 7.5 
μM, 15 μM and 30 μM could efficiently inhibit the growth of the four breast cancer cell 
lines under study but showed very low effect to the normal breast cells (MCF-10-2A). 
Furthermore, comparing the results obtained for the bLF variants we found that holo-bLF 
possessed the highest growth inhibitory activity, while bLF and apo-bLF showed higher 
inhibitory effects than LfcinB17-41 and LfcinB26-36. However, no significant differences in 
the effects of LF and apo-bLF were found in T-47D and MCF-7 cells. In addition, bLF, 
holo-bLF and apo-bLF at low concentrations (0.25 μM, 0.5 μM and 1 μM) still inhibited 
the growth of T-47D and MDA-MB-231 cells. All these results suggest that the iron 
saturation of LF has an effect on its anticancer activity depending on the cell line, and 
provided some guidelines for the study of bLF and its variants in the future. Regarding the 
possibility of bLF cytotoxicity resulting from its degraded peptides, we used SDS-PAGE 
and Tricine-SDS-PAGE to evaluate the presence of peptides from LF degradation under 
cell culture conditions. The results showed that bLF was a very stable protein even after 
incubation with cells for 72 h. Moreover, bLF and LfcinB17-41 labeled with a fluorescent 
dye could enter cells and were found to remain in cytoplasm. However, most of the protein 
stayed outside the cells, which indicated that the inhibitory effects of bLF on the breast 
cancer cells may also be due to the interaction between the protein and cell membrane or to 
the unfavorable adjustment of the cell microenvironment.   
The mechanisms underlying the bLF cytotoxicity against cancer cells have not always 
been consistent among different reports. In the current work we found that bLF exerted its 
effects by preventing the cell cycle progression. However, bLF at concentrations lower 
than 30 μM could not induce apoptosis in the cancer cells, which was further confirmed by 
the lack of effect in the JNK and p38 pathways after bLF treatment. Additionally, bLF was 
found to increase the phosphorylation of ERK and AKT, respectively, in T-47D and MCF-7 
cells in the short term. However, this increase in the signaling of these mitogenic kinases 
was not enough to counteract the inhibitory effects of bLF on the cells’ proliferation. Also, 
bLF-induced cell cycle arrest did not result from double-DNA-strand breaks. Nevertheless, 
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the bLF treatment significantly decreased the phospho-mTOR and total mTOR expressions. 
Furthermore, a key regulator upstream the mTOR pathway, phospho-AMPKα, was clearly 
increased after bLF treatment compared to the control. These effects were found to be dose 
responsive. The AMPKα/mTOR pathway plays an important role in the cells protein 
synthesis and metabolism. The results herein gathered suggest that bLF exerted its growth 
inhibitory effects through the regulation of the AMPKα/ mTOR pathway. 
Based on the above results, we hypothesized that, at higher concentration, bLF could 
exhibit different effects on the breast cancer cells. Interestingly, bLF at the concentrations 
of 12.5 μM, 50 μM, 125 μM and 175 μM induced significantly apoptosis in MCF-7 cells. 
However, no apoptotic cells were found for the remaining breast cancer cell lines used. In 
addition, in the case of the MCF-7 cells, bLF at high concentrations led to an obvious cell 
cycle arrest at the G1 phase. This was probably due to the regulation of the key proteins in 
the cell cycle progression, such as CDC25c. It is also important to mention, that we could 
confirm that bLF effects at high concentrations were not due to the interference of massive 
exogenous proteins in cell culture media. Besides, the induced apoptosis by bLF observed 
for MCF-7 cells was related with the mitochondrial membrane depolarization and the 
decrease of Bcl-2 levels. Moreover, the effect of bLF on the colony formation by MCF-7 
cells indicated that it can be a potential drug to inhibit metastasis in vivo. Simutaneously, 
the promoting effects of bLF on the migration of MCF-7 cells should not be attributed to 
its biological function. 
In short, bLF efficiently inhibited the growth of breast cancer cells through preventing 
cell cycle progression. Although it only induced apoptosis in MCF-7 cells, the growth 
inhibition of T-47D, MDA-MB-231 and Hs578T cannot be ignored. Due to its dietary 
characteristics, we believed that bLF could be used as an efficient anticancer drug or 
adjuvant in cancer therapy and prevention. 
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5.2 FUTURE PERSPECTIVES 
Prior to this study, LF has already been pointed as an efficient anticancer agent against 
other cancer cell lines. Likewise, the current work succeeded in demonstrating the bLF 
cytotoxicity against breast cancer cells, besides providing some insights on the probable 
mechanisms involved in such effect. However, there are still many unknowns that remain 
to be elucidated and that can be recommended as future research topics. 
  In this study we conducted a comparison between the bLF variants growth inhibitory 
activities, and found that holo-bLF showed the most pronounced effect. Therefore, it would 
be interesting to evaluate the anticancer effects of this bLF variant against other cancer cell 
lines. On the other hand, since it seems that iron saturation of the bLF is involved in the 
protein anticancer activity, it would be relevant to clarify the mechanisms underlying the 
bLF variants effects against cancer cells. Furthermore, although the bLF-derived peptides 
herein studied showed lowest anticancer effects as compared to the protein itself, in further 
work these peptides could be modified to exert higher cytotoxic effects, since peptides are 
advantageous over proteins for clinical applications.  
Additionally, the current work highlighted the probable mechanisms of bLF action 
against the breast cancer cells at low and high concentrations. Moreover, we found that 
bLF mainly stayed outside cells, thus probably functioning via both intracellular and 
extracellular pathways. The extracellular pathway was supposed to be the dominant one in 
the bLF anticancer activity. However, the results were not conclusive enough to confirm if 
the initial target of bLF is the cell membrane or microenvironment. The unknown signals 
lying in the upstream or downstream of the proven pathways in this study need to be 
further elucidated in the future. Moreover, both this work and most of the former reports 
were mainly conducted in vitro. Drugs usually have different performances in vivo since 
they have to go through complex steps before targeting the cancer cells, such as absorption, 
circulation in the body, metabolism and dilution in the blood. Therefore, the bLF effects 
against breast cancer have to be further evaluated through in vivo experiments.  
The results from in vitro experiments gave good indications about the bLF anticancer 
effect, but understanding its mechanism of action is crucial before a clinical application 
can be foreseen. Nevertheless, being a dietary protein there should be no limitations in its 
use at least as a preventive agent, and later in cancer therapy. We believe that its relatively 
low cytotoxic effect to cancer cells as compared with known potent anticancer drugs, as 
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well as the unspecific mechanisms regarding the bLF action, is hampering its clinical use 
in cancer treatment. LF and its derivatives could be an efficient anticancer drug if 
combined with other therapeutics, or encapsulated in carriers after appropriate 
modifications. It is interesting to notice that some studies already began to use these 
approaches to strengthen the cytotoxic effects of LF or its derivatives. While combination 
therapy is becoming more and more popular today, the food-extracted protein will exhibit 
its potential value as an adjuvant or cancer drug in cancer treatment.  
   In summary, the results gathered in this thesis made an important contribution to the 
elucidation of the mechanisms underlying the bLF effects against breast cancer cells in 
vitro. Although many issues remain to be solved before bLF is used in the clinical practice, 
the suggestions herein made represent a step forward towards that reality. Furthermore, 
considering that there are still no efficient treatment strategies for most of the cancers, bLF 
being a dietary-derived protein should be an interesting topic of research in cancer 
chemoprevention.    
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